| Year | Citation | Score | |||
|---|---|---|---|---|---|
| 2017 | Stork G, Yamashita A, Hanson RM, Phan L, Phillips E, Dubé D, Bos PH, Clark AJ, Gough M, Greenlee ML, Jiang Y, Jones K, Kitamura M, Leonard J, Liu T, et al. Synthetic Study toward Total Synthesis of (±)-Germine: Synthesis of (±)-4-Methylenegermine. Organic Letters. PMID 28876074 DOI: 10.1021/Acs.Orglett.7B02434 | 0.764 | |||
| 2015 | Leonard J, Blacker AJ, Marsden SP, Jones MF, Mulholland KR, Newton R. A Survey of the Borrowing Hydrogen Approach to the Synthesis of some Pharmaceutically Relevant Intermediates Organic Process Research and Development. 19: 1400-1410. DOI: 10.1021/Acs.Oprd.5B00199 | 0.306 | |||
| 2007 | Wilkinson J, Foretia D, Rossington S, Heagerty A, Leonard J, Hussain N, Austin C. 2'-hydroxy-fendiline analogues as potent relaxers of isolated arteries. European Journal of Pharmacology. 561: 160-3. PMID 17331497 DOI: 10.1016/J.Ejphar.2007.01.039 | 0.697 | |||
| 2007 | Wilkinson JA, Rossington SB, Coe NA, Hirst N, McGown AT, Leonard J, Hussain N. Synthesis and evaluation of 2'-substituted fendiline analogues as antileukemics Letters in Drug Design and Discovery. 4: 246-248. DOI: 10.2174/157018007784620068 | 0.749 | |||
| 2007 | Wilkinson JA, Ardes-Guisot N, Ducki S, Leonard J. Novel methods for the synthesis of 5-substituted-3-carboxy-2,5- and 4,5-dihydrothiophenes and 5-substituted 2- and 3-sulfolenes Tetrahedron. 63: 1065-1073. DOI: 10.1016/J.Tet.2006.11.061 | 0.446 | |||
| 2006 | Wilkinson JA, Rossington SB, Ducki S, Leonard J, Hussain N. Asymmetric alkylation of diarylmethane derivatives Tetrahedron. 62: 1833-1844. DOI: 10.1016/J.Tet.2005.11.044 | 0.781 | |||
| 2004 | Wilkinson JA, Rossington SB, Leonard J, Hussain N. Asymmetric alkylation of diarylmethane derivatives. Improved results using methoxyethoxy substituent Tetrahedron Letters. 45: 5481-5483. DOI: 10.1016/J.Tetlet.2004.05.058 | 0.791 | |||
| 2004 | Wilkinson JA, Rossington SB, Leonard J, Hussein N. Asymmetric alkylation of diphenylmethane derivatives using (-)-sparteine Tetrahedron Letters. 45: 1191-1193. DOI: 10.1016/J.Tetlet.2003.11.138 | 0.441 | |||
| 2004 | Wilkinson JA, Rossington SB, Ducki S, Leonard J, Hussain N. Asymmetric alkylation of N-pivaloyl-o-benzylaniline Tetrahedron Asymmetry. 15: 3011-3013. DOI: 10.1016/J.Tetasy.2004.08.020 | 0.4 | |||
| 2002 | Leonard J, Hewitt JD, Ouali D, Bennett LR, Mahmood A, Simpson SJ. Spiro epoxide fused cis bicyclo[3.3.0]octanes: Enantioselective rearrangement and utilisation of the products in synthetic adventures Tetrahedron. 58: 4681-4691. DOI: 10.1016/S0040-4020(02)00375-7 | 0.781 | |||
| 1999 | Leonard J. Recent progress in the chemistry of monoterpenoid indole alkaloids derived from secologanin Natural Product Reports. 16: 319-338. DOI: 10.1039/A707500F | 0.321 | |||
| 1999 | Leonard J, Hague AB, Harms G, Jones MF. Interesting stereoselectivity of intramolecular Diels-Alder reactions leading to 5-carbomethoxy yohimbine systems Tetrahedron Letters. 40: 8141-8145. DOI: 10.1016/S0040-4039(99)01614-7 | 0.372 | |||
| 1999 | Brown RT, Leonard J, Santos CAM. 21-α-Cyano-3-isorauniticine: a spurious heteroyohimbine structure assignment Tetrahedron Letters. 40: 7197-7200. DOI: 10.1016/S0040-4039(99)01564-6 | 0.307 | |||
| 1999 | Leonard J, Bennett L, Mahmood A. Synthesis of hirsutene — An approach involving asymmetric epoxide fragmentation Tetrahedron Letters. 40: 3965-3968. DOI: 10.1016/S0040-4039(99)00622-X | 0.519 | |||
| 1998 | Leonard J, Díez-Barra E, Merino S. Control of Asymmetry Through Conjugate Addition Reactions European Journal of Organic Chemistry. 1998: 2051-2061. DOI: 10.1002/(Sici)1099-0690(199810)1998:10<2051::Aid-Ejoc2051>3.0.Co;2-T | 0.456 | |||
| 1997 | Leonard J, Hague AB, Jones MF. A one-pot tandem Pictet-Spengler-Diels-Alder synthesis of apoyohimbines from 3-carbomethoxy-2-(formylmethyl)-3-sulfolene Tetrahedron Letters. 38: 3071-3074. DOI: 10.1016/S0040-4039(97)00547-9 | 0.486 | |||
| 1997 | Leonard J, Fearnley SP, Hague AB, Wong G, Jones MF. The geometry of dienes from 2,3-substituted-3-sulfolenes and the stereoselectivity of their intramolecular Diels-Alder cyclisations Tetrahedron Letters. 38: 3067-3070. DOI: 10.1016/S0040-4039(97)00546-7 | 0.805 | |||
| 1995 | Leonard J, Mohialdin S, Reed D, Ryan G, Swain PA. Stereoselective conjugate addition of organolithium and organocopper reagents to δ-oxygenated α,β-unsaturated carbonyl systems derived from glyceraldehyde acetonide Tetrahedron. 51: 12843-12858. DOI: 10.1016/0040-4020(95)00875-9 | 0.752 | |||
| 1994 | Leonard J, Fearnley SP, Finlay MR, Knight JA, Wong G. A sulfolene-based intramolecular Diels–Alder approach to the synthesis of manzamine A Journal of the Chemical Society-Perkin Transactions 1. 2359-2361. DOI: 10.1039/P19940002359 | 0.325 | |||
| 1994 | Leonard J, Hussain N. Total synthesis of (±)-specionin Journal of the Chemical Society, Perkin Transactions 1. 61-70. DOI: 10.1039/P19940000061 | 0.783 | |||
| 1994 | Leonard J, Hussain N. Studies on the functionalisation of cis-bicyclo[3.3.0]oct-7-en-2-ol-approaches to the synthesis of specionin Journal of the Chemical Society, Perkin Transactions 1. 49-60. DOI: 10.1039/P19940000049 | 0.754 | |||
| 1994 | Leonard J. Control of asymmetry through conjugate addition reactions Contemporary Organic Synthesis. 1: 387-415. DOI: 10.1039/Co9940100387 | 0.355 | |||
| 1994 | Leonard J, Appleton D, Fearnley SP. A short synthesis of apoyohimbines via a sulfolene based intramolecular Diels-Alder reaction Tetrahedron Letters. 35: 1071-1074. DOI: 10.1016/S0040-4039(00)79968-0 | 0.799 | |||
| 1993 | Leonard J, Mohialdin S, Reed D, Ryan G, Jones MF. Highly selective stereochemically controlled five- versus six-membered acetal ring cyclisation Journal of the Chemical Society, Chemical Communications. 23-25. DOI: 10.1039/C39930000023 | 0.776 | |||
| 1992 | Leonard J, Mohialdin S, Reed D, Jones MF. Selective Conjugate Addition of Organolithium Reagents to γ,δ-Unsaturated β-Oxo Esters Derived from Glyceraldehyde Acetonide Synlett. 1992: 741-742. DOI: 10.1055/S-1992-21476 | 0.39 | |||
| 1992 | Leonard J, Fearnley SP, Hickey DMB. Efficient preparation of useful 1,2-substituted electron-deficient dienes from sulpholenes and their use in intramolecular Diels-Alder reactions : a general approach to alkaloids Synlett. 1992: 272-274. DOI: 10.1055/S-1992-21336 | 0.781 | |||
| 1992 | Leonard J, Quali D, Rahman SK. Short enantioselective approach to heteroyohimbine alkaloids from meso-bicyclo[3.3.0]octane-3,7-dione: synthesis of methyl 2-epielenolate Journal of the Chemical Society-Perkin Transactions 1. 1203-1207. DOI: 10.1039/P19920001203 | 0.476 | |||
| 1990 | Leonard J, Ryan G, Swain PA. Stereoselective Conjugate Addition of Organolithium Reagents to Enoates Derived from Glyceraldehyde Acetonide Synlett. 1990: 613-614. DOI: 10.1055/S-1990-21185 | 0.784 | |||
| 1990 | Leonard J, Hewitt JD, Ouali D, Rahman SK, Simpson SJ, Newton RF. Useful chiral lactones derived from cis-bicyclo[3.3.0]octan-3,7-dione via asymmetric deprotonation Tetrahedron-Asymmetry. 1: 699-702. DOI: 10.1016/S0957-4166(00)82377-0 | 0.802 | |||
| 1990 | Leonard J, Hewitt JD, Ouali D, Simpson SJ, Newton RF. Enantioselective opening of spiro epoxides derived from cis bicyclo[3.3.0]octan-3,7-dione using chiral lithium amide bases Tetrahedron Letters. 31: 6703-6706. DOI: 10.1016/S0040-4039(00)97152-1 | 0.788 | |||
| 1990 | Leonard J, Ouali D, Rahman SK. A short enantioselective route to corynanthe alkaloid precursors Tetrahedron Letters. 31: 739-742. DOI: 10.1016/S0040-4039(00)94617-3 | 0.795 | |||
| 1989 | Leonard J, Mohialdin S, Swain PA. Efficient Procedures for in situ Trapping of (R)- and (S)-Glyceraldehyde acetonides by Stabilized Wittig Reagents Synthetic Communications. 19: 3529-3534. DOI: 10.1080/00397918908052762 | 0.775 | |||
| 1987 | Hussain N, Leonard J. Total synthesis of specionin - natural product or artifact ? Tetrahedron Letters. 28: 4871-4874. DOI: 10.1016/S0040-4039(00)96648-6 | 0.777 | |||
| 1987 | Leonard J, Ryan G. Asymmetric induction in acyclic Michael reactions: addition of organometallic reagents to enones derived from (R)-glyceraldehyde acetonide Tetrahedron Letters. 28: 2525-2528. DOI: 10.1016/S0040-4039(00)95458-3 | 0.8 | |||
| 1987 | Hendrie SK, Leonard J. Preparation of proline derived lithium amide bases and their use in enantioselective deprotonation of meso epoxides Tetrahedron. 43: 3289-3294. DOI: 10.1016/S0040-4020(01)90297-2 | 0.505 | |||
| 1979 | Brown RT, Leonard J. Biomimetic synthesis of cathenamine and 19-epicathenamine, key intermediates to heteroyohimbine alkaloids Journal of the Chemical Society, Chemical Communications. 877-879. DOI: 10.1039/C39790000877 | 0.325 | |||
| 1978 | Brown RT, Leonard J. Stereoconservative transformation of secologanin into meroquinene and its derivatives Journal of the Chemical Society, Chemical Communications. 725-726. DOI: 10.1039/C39780000725 | 0.445 | |||
| 1978 | Brown RT, Leonard J, Sleigh SK. The role of strictosidine in monoterpenoid indole alkaloid biosynthesis Phytochemistry. 17: 899-900. DOI: 10.1016/S0031-9422(00)88642-2 | 0.327 | |||
| 1977 | Brown RT, Leonard J, Sleigh SK. ‘One-pot’ biomimetic synthesis of 19β-heteroyohimbine alkaloids Journal of the Chemical Society, Chemical Communications. 636-638. DOI: 10.1039/C39770000636 | 0.361 | |||
| Low-probability matches (unlikely to be authored by this person) | |||||
| 1979 | Brown RT, Leonard J. On the C-16 configuration of sitsirikine Tetrahedron Letters. 20: 1805-1808. DOI: 10.1016/S0040-4039(01)86223-7 | 0.299 | |||
| 2000 | Leonard J, Hague AB, Jones MF, Ward RA. A Practical Large-Scale Synthesis of 3-Carbomethoxy-3-sulfolene Synthesis. 2000: 507-509. DOI: 10.1055/S-2000-6367 | 0.28 | |||
| 1978 | Brown RT, Leonard J. Stereoconservative Transformation Of Secologanin Into Meroquinene And Its Derivatives Cheminform. 9. DOI: 10.1002/Chin.197851213 | 0.27 | |||
| 1977 | Brown RT, Leonard J. Reversible trapping of labile 21-dehydroheteroyohimbines as 21-cyano adducts. Tetrahedron Letters. 18: 4251-4254. DOI: 10.1016/S0040-4039(01)83478-X | 0.235 | |||
| 2003 | Lewis AK, Caddick S, Cloke FG, Billingham NC, Hitchcock PB, Leonard J. Synthetic, structural, and mechanistic studies on the oxidative addition of aromatic chlorides to a palladium (N-heterocyclic carbene) complex: relevance to catalytic amination. Journal of the American Chemical Society. 125: 10066-73. PMID 12914470 DOI: 10.1021/Ja035565K | 0.169 | |||
| 2015 | Ashe KM, Budman E, Bangari DS, Siegel CS, Nietupski JB, Wang B, Desnick RJ, Scheule RK, Leonard JP, Cheng SH, Marshall J. Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease. Molecular Medicine (Cambridge, Mass.). PMID 25938659 DOI: 10.2119/Molmed.2015.00088 | 0.108 | |||
| 2017 | Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T, Robles R, Flowers CR, Collins R, DiBella NJ, Papish SW, Venugopal P, Horodner A, Tabatabai A, Hajdenberg J, et al. Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017732784. PMID 28862883 DOI: 10.1200/JCO.2017.73.2784 | 0.107 | |||
| 2020 | Armand P, Janssens AM, Gritti G, Radford J, Timmerman JM, Pinto A, Mercadal Vilchez S, Johnson PWM, Cunningham D, Leonard JP, Rodig SJ, Martín-Regueira P, Sumbul A, Samakoglu S, Tang H, et al. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood. PMID 32870269 DOI: 10.1182/blood.2019004753 | 0.097 | |||
| 2007 | Andemariam B, Leonard JP. Should all patients with indolent lymphoma be treated with rituximab maintenance therapy? An overview of the data. Clinical Lymphoma & Myeloma. S20-3. PMID 17101069 DOI: 10.3816/clm.2006.s.004 | 0.091 | |||
| 2008 | Leonard JP, Martin P, Barrientos J, Elstrom R. Targeted treatment and new agents in diffuse large B-cell lymphoma. Seminars in Hematology. 45: S11-6. PMID 18760704 DOI: 10.1053/j.seminhematol.2008.07.004 | 0.09 | |||
| 2019 | Kamdar M, Li H, Chen RW, Rimsza LM, Leblanc ML, Fenske TS, Shea TC, Barr PM, Phillips TJ, Leonard JP, Kahl BS, Friedberg JW, Smith SM. Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. Blood Advances. 3: 3132-3135. PMID 31648328 DOI: 10.1182/Bloodadvances.2019000526 | 0.088 | |||
| 2019 | Marshall J, Nietupski JB, Park H, Cao J, Bangari DS, Silvescu C, Wilper T, Randall K, Tietz D, Wang B, Ying X, Leonard JP, Cheng SH. Substrate Reduction Therapy for Sandhoff Disease through Inhibition of Glucosylceramide Synthase Activity. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 31208914 DOI: 10.1016/J.Ymthe.2019.05.018 | 0.084 | |||
| 2018 | Yamshon S, Christos PJ, Demetres M, Hammad H, Leonard JP, Ruan J. Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis. Blood Advances. 2: 1429-1438. PMID 29934343 DOI: 10.1182/bloodadvances.2018016683 | 0.082 | |||
| 2010 | Leonard JP, Martin P. Novel agents for follicular lymphoma. Hematology. American Society of Hematology. Education Program. 2010: 259-64. PMID 21239803 DOI: 10.1182/asheducation-2010.1.259 | 0.082 | |||
| 2019 | Rosenbaum CA, Jung SH, Pitcher B, Bartlett NL, Smith SM, Hsi E, Wagner-Johnston N, Thomas SP, Leonard JP, Cheson BD. Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). British Journal of Haematology. PMID 30723894 DOI: 10.1111/bjh.15768 | 0.079 | |||
| 2021 | Martin P, Bartlett NL, Chavez JC, Reagan JL, Smith SM, LaCasce AS, Jones JA, Drew J, Wu C, Mulvey E, Revuelta MV, Cerchietti L, Leonard JP. Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. Blood. PMID 34428285 DOI: 10.1182/blood.2021011679 | 0.079 | |||
| 2014 | Ruan J, Gregory SA, Christos P, Martin P, Furman RR, Coleman M, Leonard JP. Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results. Clinical Lymphoma, Myeloma & Leukemia. 14: 107-13. PMID 24373788 DOI: 10.1016/j.clml.2013.10.002 | 0.079 | |||
| 2014 | Itier JM, Ret G, Viale S, Sweet L, Bangari D, Caron A, Le-Gall F, Bénichou B, Leonard J, Deleuze JF, Orsini C. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease Journal of Inherited Metabolic Disease. 37: 1013-1022. PMID 24850378 DOI: 10.1007/s10545-014-9724-5 | 0.078 | |||
| 2005 | Leonard JP, Furman RR, Ruan J, Coleman M. New developments in immunotherapy for non-Hodgkin's lymphoma. Current Oncology Reports. 7: 364-71. PMID 16091197 DOI: 10.1007/s11912-005-0063-4 | 0.077 | |||
| 2023 | Marullo R, Rutherford SC, Revuelta MV, Zamponi N, Culijkovic B, Kotlov N, Di Siervi N, Lara-Garcia J, Allan JN, Ruan J, Furman RR, Chen Z, Shore TB, Phillips AA, Mayer S, ... ... Leonard JP, et al. XPO1 enables adaptive regulation of mRNA export required for genotoxic stress tolerance in cancer cells. Cancer Research. PMID 37801604 DOI: 10.1158/0008-5472.CAN-23-1992 | 0.077 | |||
| 2006 | Leonard JP, Furman RR, Coleman M. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. International Journal of Cancer. 119: 971-9. PMID 16557600 DOI: 10.1002/ijc.21805 | 0.076 | |||
| 2019 | Armache JP, Gamarra N, Johnson SL, Leonard JD, Wu S, Narlikar GJ, Cheng Y. Cryo-EM structures of remodeler-nucleosome intermediates suggest allosteric control through the nucleosome. Elife. 8. PMID 31210637 DOI: 10.7554/eLife.46057 | 0.076 | |||
| 2018 | Lansigan F, Barak I, Pitcher B, Jung SH, Cheson BD, Czuczman M, Martin P, Hsi E, Schöder H, Smith S, Bartlett NL, Leonard JP, Blum KA. The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials. Cancer Medicine. PMID 30575311 DOI: 10.1002/Cam4.1918 | 0.076 | |||
| 2010 | Williams ME, Dreyling M, Winter J, Muneer S, Leonard JP. Management of mantle cell lymphoma: key challenges and next steps. Clinical Lymphoma, Myeloma & Leukemia. 10: 336-46. PMID 21030346 DOI: 10.3816/Clml.2010.N.066 | 0.074 | |||
| 2011 | Andemariam B, Leonard JP. Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin's lymphoma. Biologics : Targets & Therapy. 1: 113-20. PMID 19707321 | 0.074 | |||
| 2010 | Czuczman MS, Leonard JP, Williams ME. Clinical roundtable monograph: Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion. Clinical Advances in Hematology & Oncology : H&O. 8: 1-14; quiz 2p follow. PMID 20539272 | 0.072 | |||
| 2017 | Smith SM, Pitcher BN, Jung SH, Bartlett NL, Wagner-Johnston N, Park SI, Richards KL, Cashen AF, Jaslowski A, Smith SE, Cheson BD, Hsi E, Leonard JP. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. The Lancet. Haematology. PMID 28314699 DOI: 10.1016/S2352-3026(17)30028-5 | 0.072 | |||
| 2017 | Giulino-Roth L, O'Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberley MJ, ... ... Leonard JP, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. British Journal of Haematology. PMID 29082519 DOI: 10.1111/Bjh.14951 | 0.071 | |||
| 2010 | Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 116: 106-14. PMID 19890959 DOI: 10.1002/Cncr.24714 | 0.07 | |||
| 2014 | Racki LR, Naber N, Pate E, Leonard JD, Cooke R, Narlikar GJ. The histone H4 tail regulates the conformation of the ATP-binding pocket in the SNF2h chromatin remodeling enzyme. Journal of Molecular Biology. 426: 2034-44. PMID 24607692 DOI: 10.1016/J.Jmb.2014.02.021 | 0.069 | |||
| 2008 | Martin P, Furman RR, Ruan J, Elstrom R, Barrientos J, Niesvizky R, Coleman M, Leonard JP. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. Seminars in Hematology. 45: 126-32. PMID 18381108 DOI: 10.1053/j.seminhematol.2008.02.007 | 0.069 | |||
| 2016 | Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, ... ... Leonard JP, et al. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. British Journal of Haematology. PMID 27992063 DOI: 10.1111/bjh.14480 | 0.068 | |||
| 2015 | Fisher TL, Reilly CA, Winter LA, Pandina T, Jonason A, Scrivens M, Balch L, Bussler H, Torno S, Seils J, Mueller L, Huang H, Klimatcheva E, Howell A, Kirk R, ... ... Leonard JE, et al. Generation and preclinical characterization of an antibody specific for SEMA4D. Mabs. 0. PMID 26431358 DOI: 10.1080/19420862.2015.1102813 | 0.068 | |||
| 2008 | Elstrom RL, Martin P, Leonard JP. New biologic agents and immunologic strategies. Hematology/Oncology Clinics of North America. 22: 1037-49, x-xi. PMID 18954750 DOI: 10.1016/j.hoc.2008.07.003 | 0.067 | |||
| 2021 | Nowakowski GS, Hong F, Scott DW, Macon WR, King RL, Habermann TM, Wagner-Johnston N, Casulo C, Wade JL, Nagargoje GG, Reynolds CM, Cohen JB, Khan N, Amengual JE, Richards KL, ... ... Leonard JP, et al. Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001375. PMID 33555941 DOI: 10.1200/JCO.20.01375 | 0.066 | |||
| 2022 | Epperla N, Switchenko JM, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews SP, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, ... ... Leonard JP, et al. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood Advances. PMID 36516079 DOI: 10.1182/bloodadvances.2022009225 | 0.066 | |||
| 2018 | Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, Spier CM, Gopal AK, Maloney DG, Cheson BD, Dakhil S, LeBlanc M, Smith SM, Fisher RI, Friedberg JW, et al. Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017745083. PMID 29356608 DOI: 10.1200/JCO.2017.74.5083 | 0.066 | |||
| 2009 | Ruan J, Coleman M, Leonard JP. Management of relapsed mantle cell lymphoma: still a treatment challenge. Oncology (Williston Park, N.Y.). 23: 683-90. PMID 19711582 | 0.066 | |||
| 2017 | Ghione P, Cavallo F, Visco C, Chen Z, Castellino A, Tisi MC, Dogliotti I, Nicolosi M, Boccadoro M, Leonard JP, Vitolo U, Martin P. A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma. British Journal of Haematology. PMID 29265185 DOI: 10.1111/bjh.15057 | 0.065 | |||
| 2020 | Kroft SH, Sever CE, Bagg A, Billman B, Diefenbach C, Dorfman DM, Finn WG, Gratzinger DA, Gregg PA, Leonard JP, Smith S, Souter L, Weiss RL, Ventura CB, Cheung MC. Laboratory Workup of Lymphoma in Adults. American Journal of Clinical Pathology. PMID 33219376 DOI: 10.1093/ajcp/aqaa191 | 0.065 | |||
| 2013 | Ruan J, Luo M, Wang C, Fan L, Yang SN, Cardenas M, Geng H, Leonard JP, Melnick A, Cerchietti L, Hajjar KA. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood. 121: 5192-202. PMID 23632889 DOI: 10.1182/Blood-2013-03-490763 | 0.065 | |||
| 2020 | Kroft SH, Sever CE, Bagg A, Billman B, Diefenbach C, Dorfman DM, Finn WG, Gratzinger DA, Gregg PA, Leonard JP, Smith S, Souter L, Weiss RL, Ventura CB, Cheung MC. Laboratory Workup of Lymphoma in Adults. Archives of Pathology & Laboratory Medicine. PMID 33175094 DOI: 10.5858/arpa.2020-0261-SA | 0.065 | |||
| 2019 | Leonard JP. New developments in the treatment of follicular lymphoma. [Rinsho Ketsueki] the Japanese Journal of Clinical Hematology. 60: 1199-1204. PMID 31597844 DOI: 10.11406/rinketsu.60.1199 | 0.064 | |||
| 2016 | Marshall J, Sun Y, Bangari DS, Budman E, Park H, Nietupski JB, Allaire A, Cromwell MA, Wang B, Grabowski GA, Leonard JP, Cheng SH. CNS-Accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 26948439 DOI: 10.1038/mt.2016.53 | 0.063 | |||
| 2015 | Bangari DS, Ashe KM, Desnick RJ, Maloney C, Lydon J, Piepenhagen P, Budman E, Leonard JP, Cheng SH, Marshall J, Thurberg BL. α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease. The American Journal of Pathology. 185: 651-65. PMID 25553976 DOI: 10.1016/J.Ajpath.2014.11.004 | 0.062 | |||
| 2016 | Puvvada SD, Stiff PJ, Leblanc M, Cook JR, Couban S, Leonard JP, Kahl B, Marcellus D, Shea TC, Winter JN, Li H, Rimsza LM, Friedberg JW, Smith SM. Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. British Journal of Haematology. PMID 27072903 DOI: 10.1111/Bjh.14100 | 0.062 | |||
| 2020 | de Vos S, Leonard JP, Friedberg JW, Zain J, Dunleavy K, Humerickhouse R, Hayslip J, Pesko J, Wilson WH. Safety and efficacy of navitoclax, a BCL-2 and BCL-X inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study. Leukemia & Lymphoma. 1-9. PMID 33236943 DOI: 10.1080/10428194.2020.1845332 | 0.062 | |||
| 2007 | Martin P, Leonard JP. Targeted therapies for non-Hodgkin lymphoma: rationally designed combinations. Clinical Lymphoma & Myeloma. S192-8. PMID 17877844 DOI: 10.3816/CLM.2007.S.022 | 0.061 | |||
| 2013 | Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, Wyman S, Leser M, Shaknovich R, Chadburn A, Tabbo F, ... ... Leonard JP, et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discovery. 3: 1002-19. PMID 23955273 DOI: 10.1158/2159-8290.Cd-13-0117 | 0.061 | |||
| 2022 | Lieberman R, Cortes LK, Gao G, Park H, Wang B, Jones PL, Hunter RB, Leonard JP, Barker RH. Human iPSC-derived astrocytes generated from donors with globoid cell leukodystrophy display phenotypes associated with disease. Plos One. 17: e0271360. PMID 35921286 DOI: 10.1371/journal.pone.0271360 | 0.06 | |||
| 2015 | Ruan J, Martin P, Shah B, Schuster SJ, Smith SM, Furman RR, Christos P, Rodriguez A, Svoboda J, Lewis J, Katz O, Coleman M, Leonard JP. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. The New England Journal of Medicine. 373: 1835-44. PMID 26535512 DOI: 10.1056/NEJMoa1505237 | 0.06 | |||
| 2020 | Kaplan LD, Maurer MJ, Stock W, Bartlett NL, Fulton N, Pettinger A, Byrd JC, Blum KA, LaCasce AS, Hsi ED, Liu YT, Scott DW, Hurd D, Ruppert AS, Hernandez-Ilizaliturri F, ... Leonard JP, et al. Bortezomib Consolidation or Maintenance Following Immunochemotherapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: CALGB/Alliance 50403. American Journal of Hematology. PMID 32170769 DOI: 10.1002/ajh.25783 | 0.06 | |||
| 2016 | Nowakowski GS, Blum KA, Kahl BS, Friedberg JW, Baizer L, Little RF, Maloney DG, Sehn LH, Williams ME, Wilson WH, Leonard JP, Smith SM. Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. Journal of the National Cancer Institute. 108. PMID 27986884 DOI: 10.1093/jnci/djw257 | 0.059 | |||
| 2018 | Coutre SE, Flinn IW, de Vos S, Barrientos JC, Schreeder MT, Wagner-Johnson ND, Sharman JP, Boyd TE, Fowler N, Dreiling L, Kim Y, Mitra S, Rai K, Leonard JP, Furman RR. Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. Hemasphere. 2: e39. PMID 31723767 DOI: 10.1097/HS9.0000000000000039 | 0.059 | |||
| 2016 | Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, et al. Post-ibrutinib outcomes in patients with mantle cell lymphoma. Blood. PMID 26764355 DOI: 10.1182/blood-2015-10-673145 | 0.059 | |||
| 2005 | Leonard JP. Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 335-339. PMID 16304400 | 0.059 | |||
| 2015 | Dupont T, Yang S, Patel J, Hatzi K, Malik A, Tam W, Martin P, Leonard J, Melnick A, Cerchietti L. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. Oncotarget. PMID 26657288 DOI: 10.18632/Oncotarget.6513 | 0.059 | |||
| 2013 | Grant BW, Jung SH, Johnson JL, Kostakoglu L, Hsi E, Byrd JC, Jones J, Leonard JP, Martin SE, Cheson BD. A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer. 119: 3797-804. PMID 23922187 DOI: 10.1002/cncr.28299 | 0.059 | |||
| 2008 | Leonard JP, Gregory SA, Maloney DG, Vose JM, Younes A, Zelenetz AD. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma. Clinical Advances in Hematology & Oncology : H&O. 6: 437-45. PMID 18567989 | 0.058 | |||
| 2018 | Flowers CR, Leonard JP, Nastoupil LJ. Novel immunotherapy approaches to follicular lymphoma. Hematology. American Society of Hematology. Education Program. 2018: 194-199. PMID 30504310 DOI: 10.1182/asheducation-2018.1.194 | 0.058 | |||
| 2016 | Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang SN, Cohen J, Shaknovich R, Vanommeslaeghe K, Cheng H, Liang D, Cho HJ, ... ... Leonard JP, et al. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. The Journal of Clinical Investigation. PMID 27482887 DOI: 10.1172/Jci85795 | 0.057 | |||
| 2017 | Keeley T, Russell T, Carmody K, Kirk G, Eastley T, Britt-Lewis A, Post M, Burridge M, Eccleston S, Faulkner T, Forge T, Leonard J, Hughes RL. Seasonality and breeding success of captive and wild Tasmanian devils (Sarcophilus harrisii). Theriogenology. 95: 33-41. PMID 28460677 DOI: 10.1016/j.theriogenology.2017.02.013 | 0.057 | |||
| 2016 | Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. The Lancet. Haematology. PMID 27914971 DOI: 10.1016/S2352-3026(16)30166-1 | 0.057 | |||
| 2013 | Cerchietti L, Leonard JP. Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP. Hematology. American Society of Hematology. Education Program. 2013: 591-5. PMID 24319236 DOI: 10.1182/asheducation-2013.1.591 | 0.055 | |||
| 2021 | Rutherford SC, Abramson JS, Bartlett NL, Barta SK, Khan N, Joyce R, Maddocks K, Ali-Shaw T, Senese S, Yuan Y, Westin J, Leonard JP. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. The Lancet. Haematology. PMID 34634256 DOI: 10.1016/S2352-3026(21)00273-8 | 0.055 | |||
| 2015 | Troxell-Smith SM, Tutka MJ, Albergo JM, Balu D, Brown JS, Leonard JP. Foraging decisions in wild versus domestic Mus musculus: What does life in the lab select for? Behavioural Processes. PMID 26548716 DOI: 10.1016/J.Beproc.2015.10.020 | 0.055 | |||
| 2019 | Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, ... ... Leonard JP, et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801994. PMID 30939090 DOI: 10.1200/Jco.18.01994 | 0.055 | |||
| 2011 | Nelson CA, Hunter RB, Quigley LA, Girgenrath S, Weber WD, McCullough JA, Dinardo CJ, Keefe KA, Ceci L, Clayton NP, McVie-Wylie A, Cheng SH, Leonard JP, Wentworth BM. Inhibiting TGF-β activity improves respiratory function in mdx mice. The American Journal of Pathology. 178: 2611-21. PMID 21641384 DOI: 10.1016/j.ajpath.2011.02.024 | 0.055 | |||
| 2007 | Martin P, Furman RR, Coleman M, Leonard JP. Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5636s-5642s. PMID 17875800 DOI: 10.1158/1078-0432.CCR-07-1085 | 0.054 | |||
| 2017 | Maddocks K, Barr PM, Cheson BD, Little RF, Baizer L, Kahl BS, Leonard JP, Fowler N, Gordon LI, Link BK, Friedberg JW, Ansell SM. Recommendations for Clinical Trial Development in Follicular Lymphoma. Journal of the National Cancer Institute. 109. PMID 28040699 DOI: 10.1093/jnci/djw255 | 0.054 | |||
| 2006 | Khan KD, Emmanouilides C, Benson DM, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, et al. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 7046-53. PMID 17145827 DOI: 10.1158/1078-0432.Ccr-06-1571 | 0.054 | |||
| 2010 | Furman RR, Martin P, Ruan J, Cheung YK, Vose JM, LaCasce AS, Elstrom R, Coleman M, Leonard JP. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer. 116: 5432-9. PMID 20665890 DOI: 10.1002/cncr.25509 | 0.054 | |||
| 2014 | Hosein PJ, Maragulia JC, Salzberg MP, Press OW, Habermann TM, Vose JM, Bast M, Advani RH, Tibshirani R, Evens AM, Islam N, Leonard JP, Martin P, Zelenetz AD, Lossos IS. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. British Journal of Haematology. 165: 358-63. PMID 24467658 DOI: 10.1111/Bjh.12753 | 0.053 | |||
| 2002 | Leonard JP, Link BK. Immunotherapy of non-hodgkin's lymphoma with hll2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu I D 1 0 (apolizumab) Seminars in Oncology. 29: 81-86. PMID 11842393 | 0.053 | |||
| 2019 | Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, et al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900010. PMID 30897038 DOI: 10.1200/JCO.19.00010 | 0.053 | |||
| 2005 | Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, Leonard JP, Kroll S, Goldsmith SJ, Coleman M. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7565-73. PMID 16186600 DOI: 10.1200/JCO.2004.00.9217 | 0.053 | |||
| 2019 | Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, Leblanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi E, Leonard JP, Kahl B, et al. . Blood. PMID 31331918 DOI: 10.1182/Blood.2019000719 | 0.052 | |||
| 2017 | Sholle ET, Kabariti J, Johnson SB, Leonard JP, Pathak J, Varughese VI, Cole CL, Campion TR. Secondary Use of Patients' Electronic Records (SUPER): An Approach for Meeting Specific Data Needs of Clinical and Translational Researchers. Amia ... Annual Symposium Proceedings. Amia Symposium. 2017: 1581-1588. PMID 29854228 | 0.052 | |||
| 2019 | Leonard JP, Link BK. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Seminars in Oncology. 29: 81-86. PMID 28140096 DOI: 10.1053/sonc.2002.30149 | 0.052 | |||
| 2018 | Leonard JP, Nastoupil LJ, Flowers CR. Where to start? Upfront therapy for follicular lymphoma in 2018. Hematology. American Society of Hematology. Education Program. 2018: 185-188. PMID 30504308 DOI: 10.1182/asheducation-2018.1.185 | 0.052 | |||
| 2015 | Reiss J, Link B, Ruan J, Furman R, Coleman M, Leonard J, Martin P. Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma. Leukemia & Lymphoma. 1-6. PMID 25676037 DOI: 10.3109/10428194.2015.1016929 | 0.051 | |||
| 2003 | Coleman M, Leonard J, Lyons L, Pekle K, Nahum K, Pearse R, Niesvizky R, Michaeli J. BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia. Leukemia & Lymphoma. 43: 1777-82. PMID 12685831 DOI: 10.1080/1042819021000006303 | 0.051 | |||
| 2020 | Sohani AR, Maurer MJ, Giri S, Pitcher B, Chadburn A, Said JW, Bartlett NL, Czuczman MS, Martin P, Rosenbaum CA, Jung SH, Leonard JP, Cheson BD, Hsi ED. Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. The American Journal of Surgical Pathology. PMID 33136585 DOI: 10.1097/PAS.0000000000001609 | 0.05 | |||
| 2023 | Soliman E, Leonard J, Basso EK, Gershenson I, Ju J, Mills J, Jager C, Kaloss AM, Elhassanny M, Pereira D, Chen M, Wang X, Theus MH. Efferocytosis is restricted by axon guidance molecule EphA4 via ERK/Stat6/Mertk signaling following brain injury. Research Square. PMID 37461720 DOI: 10.21203/rs.3.rs-3079466/v1 | 0.05 | |||
| 2015 | Martin P, Furman RR, Rutherford S, Ruan J, Ely S, Greenberg J, Coleman M, Goldsmith SJ, Leonard JP. Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas. Leukemia & Lymphoma. 1-6. PMID 25754579 DOI: 10.3109/10428194.2015.1028052 | 0.05 | |||
| 2006 | Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3107-12. PMID 16754937 DOI: 10.1200/JCO.2005.04.4289 | 0.05 | |||
| 2018 | Rutherford SC, Leonard JP. DLBCL Cell of Origin: What Role Should It Play in Care Today? Oncology (Williston Park, N.Y.). 32. PMID 30248164 | 0.05 | |||
| 2017 | Spurgeon SE, Till BG, Martin P, Goy AH, Dreyling MP, Gopal AK, LeBlanc M, Leonard JP, Friedberg JW, Baizer L, Little RF, Kahl BS, Smith MR. Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. Journal of the National Cancer Institute. 109. PMID 28040733 DOI: 10.1093/Jnci/Djw263 | 0.05 | |||
| 2009 | Martin P, Leonard JP, Coleman M, Furman RR. Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsis. Clinical Lymphoma & Myeloma. 9: 247-9. PMID 19525196 DOI: 10.3816/CLM.2009.n.049 | 0.05 | |||
| 2011 | Chai L, McLaren RP, Byrne A, Chuang WL, Huang Y, Dufault MR, Pacheco J, Madhiwalla S, Zhang X, Zhang M, Teicher BA, Carter K, Cheng SH, Leonard JP, Xiang Y, et al. The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function. International Journal of Oncology. 38: 701-11. PMID 21186402 DOI: 10.3892/Ijo.2010.888 | 0.049 | |||
| 2010 | Natoli TA, Smith LA, Rogers KA, Wang B, Komarnitsky S, Budman Y, Belenky A, Bukanov NO, Dackowski WR, Husson H, Russo RJ, Shayman JA, Ledbetter SR, Leonard JP, Ibraghimov-Beskrovnaya O. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nature Medicine. 16: 788-92. PMID 20562878 DOI: 10.1038/nm.2171 | 0.049 | |||
| 2017 | Martin P, Chen Z, Cheson BD, Robinson KS, Williams M, Rajguru SA, Friedberg JW, van der Jagt RH, LaCasce AS, Joyce R, Ganjoo KN, Bartlett NL, Lemieux B, VanderWalde A, Herst J, ... ... Leonard JP, et al. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. British Journal of Haematology. PMID 28419413 DOI: 10.1111/bjh.14667 | 0.049 | |||
| 2022 | Mills J, Ladner L, Soliman E, Leonard J, Morton PD, Theus MH. Cross-Talk and Subset Control of Microglia and Associated Myeloid Cells in Neurological Disorders. Cells. 11. PMID 36359758 DOI: 10.3390/cells11213364 | 0.049 | |||
| 2021 | Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, ... ... Leonard JP, et al. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplantation. PMID 34413469 DOI: 10.1038/s41409-021-01288-9 | 0.049 | |||
| 2019 | Chen C, Turner SP, Sholle ET, Brown SW, Blau VLI, Brouwer JP, Lewis AN, Cole CL, Nanus DM, Shah MA, Leonard JP, Campion TR. Evaluation of a REDCap-based Workflow for Supporting Federal Guidance for Electronic Informed Consent. Amia Joint Summits On Translational Science Proceedings. Amia Joint Summits On Translational Science. 2019: 163-172. PMID 31258968 | 0.049 | |||
| 2003 | Coleman M, Goldenberg DM, Siegel AB, Ketas JC, Ashe M, Fiore JM, Leonard JP. Epratuzumab: Targeting B-cell malignancies through CD22 Clinical Cancer Research. 9: 3991s-3994s. PMID 14506198 | 0.049 | |||
| 2007 | Martin P, Leonard JP. Novel therapeutic targets in mantle cell lymphoma. Expert Opinion On Therapeutic Targets. 11: 929-40. PMID 17614761 DOI: 10.1517/14728222.11.7.929 | 0.048 | |||
| 2022 | Shaaban A, Schultz J, Leonard J, Martin CM, Kamdar F, Alexy T, Thenappan T, Pritzker M, Shaffer A, John R, Cogswell R. Outcomes of Patients Referred for Cardiac Rehabilitation after Left Ventricular Assist Device Implantation. Asaio Journal (American Society For Artificial Internal Organs : 1992). PMID 35920751 DOI: 10.1097/MAT.0000000000001799 | 0.048 | |||
| 2022 | Kowalski EA, Soliman E, Kelly C, Gudenschwager Basso EK, Leonard J, Pridham KJ, Ju J, Cash AM, Hazy A, de Jager C, Kaloss AM, Ding H, Hernandez RD, Coleman GM, Wang X, et al. Monocyte pro-inflammatory phenotypic control by Ephrin type-A receptor 4 mediates neural tissue damage. Jci Insight. PMID 35737458 DOI: 10.1172/jci.insight.156319 | 0.048 | |||
| 2022 | Stephens DM, Li H, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, Song JY, LeBlanc ML, Smith SM, Persky DO, Friedberg JW. Extranodal presentation in limited stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001. Haematologica. PMID 35833300 DOI: 10.3324/haematol.2022.281004 | 0.048 | |||
| 2011 | Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 117: 2807-12. PMID 21239695 DOI: 10.1182/Blood-2010-11-314708 | 0.048 | |||
| 2003 | Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Cesano A, Goldenberg DM. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 3051-9. PMID 12837807 DOI: 10.1200/JCO.2003.01.082 | 0.048 | |||
| 2019 | O'Connor OA, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, ... ... Leonard JP, et al. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1800899. PMID 30707661 DOI: 10.1200/Jco.18.00899 | 0.048 | |||
| 2006 | Ruan J, Hyjek E, Kermani P, Christos PJ, Hooper AT, Coleman M, Hempstead B, Leonard JP, Chadburn A, Rafii S. Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma Clinical Cancer Research. 12: 5622-5631. PMID 17020964 DOI: 10.1158/1078-0432.Ccr-06-1204 | 0.047 | |||
| 2005 | Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR, Schuster MW, Niesvizky R, Muss D, Fiore J, Kroll S, Tidmarsh G, Vallabhajosula S, Goldsmith SJ. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5696-704. PMID 16110029 DOI: 10.1200/Jco.2005.14.803 | 0.047 | |||
| 2023 | Burack WR, Li H, Adlowitz DG, Spence JM, Rimsza LM, Shadman M, Spier C, Kaminski MS, Leonard JP, Leblanc M, Smith SM, Friedberg JW. Subclonal TP53 mutation are frequent and predict resistance to radio-immunotherapy in follicular lymphoma. Blood Advances. PMID 37379264 DOI: 10.1182/bloodadvances.2022009467 | 0.047 | |||
| 2003 | Siegel AB, Goldenberg DM, Cesano A, Coleman M, Leonard JP. CD22-directed monoclonal antibody therapy for lymphoma. Seminars in Oncology. 30: 457-64. PMID 12939714 DOI: 10.1016/s0093-7754(03)00240-9 | 0.046 | |||
| 2012 | Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 119: 4597-607. PMID 22383795 DOI: 10.1182/blood-2011-10-388298 | 0.046 | |||
| 2008 | Leonard JP, Schuster SJ, Emmanouilides C, Couture F, Teoh N, Wegener WA, Coleman M, Goldenberg DM. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer. 113: 2714-23. PMID 18853418 DOI: 10.1002/cncr.23890 | 0.046 | |||
| 2023 | Ruan J, Moskowitz AJ, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, Nos G, Sorokina M, Maksimov V, Sboner A, Sigouros M, van Besien K, Horwitz SM, Rutherford SC, Mulvey E, ... ... Leonard JP, et al. Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma. Blood. PMID 36796016 DOI: 10.1182/blood.2022018254 | 0.045 | |||
| 2017 | Martin P, Ruan J, Leonard JP. The potential for chemotherapy-free strategies in mantle cell lymphoma. Blood. PMID 28899853 DOI: 10.1182/blood-2017-05-737510 | 0.045 | |||
| 2015 | Fisher TL, Seils J, Reilly C, Litwin V, Green L, Salkowitz-Bokal J, Walsh R, Harville S, Leonard JE, Smith E, Zauderer M. Saturation monitoring of VX15/2503, a novel semaphorin 4D-specific antibody, in clinical trials. Cytometry. Part B, Clinical Cytometry. PMID 26566052 DOI: 10.1002/Cyto.B.21338 | 0.045 | |||
| 2018 | Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, Schuster SJ, Rodriguez A, Hyman D, Calvo-Vidal MN, Smith SM, Svoboda J, Furman RR, Coleman M, Leonard JP. Five-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma. Blood. PMID 30181173 DOI: 10.1182/blood-2018-07-859769 | 0.044 | |||
| 2012 | Diefenbach CS, Leonard JP. Targeting CD30 in hodgkin lymphoma: antibody-drug conjugates make a difference. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Meeting. 162-6. PMID 24451728 DOI: 10.14694/EdBook_AM.2012.32.162 | 0.044 | |||
| 2012 | Cabrera-Salazar MA, Deriso M, Bercury SD, Li L, Lydon JT, Weber W, Pande N, Cromwell MA, Copeland D, Leonard J, Cheng SH, Scheule RK. Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. Plos One. 7: e43310. PMID 22912851 DOI: 10.1371/journal.pone.0043310 | 0.044 | |||
| 2004 | Furman RR, Coleman M, Leonard JP. Epratuzumab in non-Hodgkin's lymphomas. Current Treatment Options in Oncology. 5: 283-8. PMID 15233905 DOI: 10.1007/S11864-004-0019-1 | 0.043 | |||
| 2012 | Cols M, Barra CM, He B, Puga I, Xu W, Chiu A, Tam W, Knowles DM, Dillon SR, Leonard JP, Furman RR, Chen K, Cerutti A. Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. Journal of Immunology (Baltimore, Md. : 1950). 188: 6071-83. PMID 22593611 DOI: 10.4049/Jimmunol.1102066 | 0.043 | |||
| 2017 | Valls E, Lobry C, Geng H, Wang L, Cardenas M, Rivas M, Cerchietti L, Oh P, Yang SN, Oswald E, Graham CW, Jiang Y, Hatzi K, Agirre X, Perkey E, ... ... Leonard JP, et al. BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. Cancer Discovery. PMID 28232365 DOI: 10.1158/2159-8290.Cd-16-1189 | 0.043 | |||
| 2019 | Toure A, Ghione P, Phillips S, Klute K, Leonard JP, Martin P. Lymphoma Study Titles on ClinicalTrials.gov Lack Details Necessary for Study Identification. Clinical Lymphoma, Myeloma & Leukemia. PMID 31836450 DOI: 10.1016/j.clml.2019.11.011 | 0.042 | |||
| 2009 | Mark T, Martin P, Leonard JP, Niesvizky R. Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. Expert Opinion On Investigational Drugs. 18: 99-104. PMID 19053886 DOI: 10.1517/13543780802636162 | 0.042 | |||
| 2005 | Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, Niesvizky R, Shore T, Chadburn A, Horne H, Kovacs J, Ding CL, Wegener WA, Horak ID, Goldenberg DM. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma Journal of Clinical Oncology. 23: 5044-5051. PMID 15955901 DOI: 10.1200/JCO.2005.13.821 | 0.042 | |||
| 2009 | Leonard JP, Williams ME, Goy A, Grant S, Pfreundschuh M, Rosen ST, Sweetenham JW. Mantle cell lymphoma: biological insights and treatment advances. Clinical Lymphoma & Myeloma. 9: 267-77. PMID 19717376 DOI: 10.3816/Clm.2009.N.055 | 0.041 | |||
| 2013 | Chiron D, Martin P, Di Liberto M, Huang X, Ely S, Lannutti BJ, Leonard JP, Mason CE, Chen-Kiang S. Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. Cell Cycle (Georgetown, Tex.). 12: 1892-900. PMID 23676220 DOI: 10.4161/cc.24928 | 0.041 | |||
| 2011 | Martin P, Leonard J. Is there a role for "watch and wait" in patients with mantle cell lymphoma? Seminars in Hematology. 48: 189-93. PMID 21782061 DOI: 10.1053/j.seminhematol.2011.03.010 | 0.041 | |||
| 2023 | Yamshon S, Chen G, Gribbin C, Christos P, Shah BD, Schuster SJ, Smith SM, Svoboda J, Furman RR, Leonard JP, Martin P, Ruan J. Nine-year Follow-up of Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma. Blood Advances. PMID 37682791 DOI: 10.1182/bloodadvances.2023010606 | 0.041 | |||
| 2007 | Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J, Zafar F, Mark T, Lent R, Pearse RN, Ely S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. British Journal of Haematology. 138: 640-3. PMID 17686058 DOI: 10.1111/j.1365-2141.2007.06698.x | 0.041 | |||
| 2016 | de Vos S, Wagner-Johnston ND, Coutre SE, Flinn IW, Schreeder MT, Fowler NH, Sharman JP, Boccia RV, Barrientos JC, Rai KR, Boyd TE, Furman RR, Kim Y, Godfrey WR, Leonard JP. Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma. Blood Advances. 1: 122-131. PMID 29296805 DOI: 10.1182/bloodadvances.2016000976 | 0.041 | |||
| 2009 | Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3346-53. PMID 19451441 DOI: 10.1200/JCO.2008.19.9117 | 0.041 | |||
| 2009 | Ruan J, Leonard J. Targeting angiogenesis: A novel, rational therapeutic approach for non-Hodgkin lymphoma Leukemia and Lymphoma. 50: 679-681. PMID 19452312 DOI: 10.1080/10428190902893835 | 0.04 | |||
| 2004 | Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, Feldman EJ, Ashe M, Schuster SJ, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Fields SZ, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results Clinical Cancer Research. 10: 5327-5334. PMID 15328168 DOI: 10.1158/1078-0432.CCR-04-0294 | 0.04 | |||
| 2010 | Leonard JW. Defining disabled: a study of the ADA Amendments Act of 2008 in eliminating the consideration of certain mitigating measures. The Journal of Contemporary Health Law and Policy. 26: 125-47. PMID 20112621 | 0.04 | |||
| 2024 | Cerhan JR, Maurer MJ, Link BK, Feldman AL, Habermann TM, Jaye DL, Burack WR, McDonnell TJ, Vega F, Chapman JR, Syrbu S, Vij KR, Inghirami G, Leonard JP, Bernal-Mizrachi L, et al. The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes. American Journal of Hematology. PMID 38217361 DOI: 10.1002/ajh.27202 | 0.04 | |||
| 2016 | Ujjani CS, Jung SH, Pitcher B, Martin P, Park SI, Blum KA, Smith SM, Czuczman M, Davids MS, Levine E, Lewis LD, Smith SE, Bartlett NL, Leonard JP, Cheson BD. Phase I trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. Blood. PMID 27697771 DOI: 10.1182/Blood-2016-06-718106 | 0.04 | |||
| 2009 | Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5410-7. PMID 19826128 DOI: 10.1200/JCO.2008.21.6150 | 0.04 | |||
| 2003 | Leonard JP, Siegel JA, Goldsmith SJ. Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: Implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma Cancer Investigation. 21: 241-252. PMID 12743990 DOI: 10.1081/CNV-120016421 | 0.04 | |||
| 2009 | Hasan A, Michel M, Patel V, Stasi R, Cunningham-Rundles S, Leonard JP, Bussel J. Repeated courses of rituximab in chronic ITP: Three different regimens. American Journal of Hematology. 84: 661-5. PMID 19731307 DOI: 10.1002/ajh.21512 | 0.04 | |||
| 2015 | Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, Popplewell L, Siddiqi T, Thomas SH, Mott M, Sahebi F, Armenian S, Leonard J, Nademanee A, Forman SJ. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26211987 DOI: 10.1016/j.bbmt.2015.07.018 | 0.04 | |||
| 2016 | Sturgeon KM, Schweitzer A, Leonard JJ, Tobias DK, Liu Y, Cespedes E, Malik VS, Joshi A, Rosner B, De Jonghe BC. Physical activity induced protection against breast cancer risk associated with delayed parity. Physiology & Behavior. PMID 27884590 DOI: 10.1016/J.Physbeh.2016.11.026 | 0.04 | |||
| 2020 | Schöder H, Polley MY, Knopp MV, Hall NC, Kostakoglu L, Zhang J, Higley HR, Kelloff G, Liu H, Zelenetz A, Cheson BD, Wagner-Johnston ND, Kahl B, Friedberg JW, Hsi ED, ... Leonard JP, et al. Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results from the CALGB 50303 Clinical Trial. Blood. PMID 32232481 DOI: 10.1182/Blood.2019003277 | 0.039 | |||
| 2007 | Roboz GJ, Bennett JM, Coleman M, Ritchie EK, Furman RR, Rossi A, Jhaveri K, Feldman EJ, Leonard JP. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. Leukemia Research. 31: 1141-4. PMID 17475326 DOI: 10.1016/j.leukres.2006.11.011 | 0.039 | |||
| 2005 | Kaminski MS, Radford JA, Gregory SA, Leonard JP, Knox SJ, Kroll S, Wahl RL. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7985-93. PMID 16204016 DOI: 10.1200/JCO.2005.01.0892 | 0.039 | |||
| 2005 | Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM, Capizzi RL. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 105: 4576-82. PMID 15731177 DOI: 10.1182/blood-2004-12-4690 | 0.039 | |||
| 2014 | Holland RA, Leonard JJ, Kensey NA, Hannikainen PA, De Jonghe BC. Cisplatin induces neuronal activation and increases central AMPA and NMDA receptor subunit gene expression in mice. Physiology & Behavior. 136: 79-85. PMID 24582677 DOI: 10.1016/j.physbeh.2014.02.038 | 0.039 | |||
| 2006 | Furman RR, Coleman M, Muss D, Leonard JP. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Cancer Treatment and Research. 131: 221-50. PMID 16704171 | 0.038 | |||
| 2008 | Mark T, Jayabalan D, Coleman M, Pearse RN, Wang YL, Lent R, Christos PJ, Lee JW, Agrawal YP, Matthew S, Ely S, Mazumdar M, Cesarman E, Leonard JP, Furman RR, et al. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. British Journal of Haematology. 143: 654-60. PMID 18950461 DOI: 10.1111/J.1365-2141.2008.07374.X | 0.038 | |||
| 2017 | Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, Advani RH, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard JI, et al. Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Cancer. PMID 28902390 DOI: 10.1002/cncr.30979 | 0.038 | |||
| 2016 | Marullo R, Rutherford SC, Leonard JP, Cerchietti L. Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas. Cell Cycle (Georgetown, Tex.). 0. PMID 27419806 DOI: 10.1080/15384101.2016.1207839 | 0.038 | |||
| 2021 | Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, ... ... Leonard JP, et al. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. Transplantation and Cellular Therapy. 27: 720-728. PMID 34452722 DOI: 10.1016/j.jtct.2021.03.001 | 0.038 | |||
| 2012 | Leonard JP. Is rituximab maintenance still standard of care in indolent non-hodgkin lymphoma? Clinical Advances in Hematology & Oncology : H&O. 10: 540-2. PMID 23073054 | 0.038 | |||
| 2008 | Lin A, Kadam JS, Bodenheimer HC, Leonard J, Joyce MA, Lake-Bakaar G. Concomitant diffuse large B-cell lymphoma and hepatocellular carcinoma in chronic hepatitis C virus liver disease: a study of two cases. Journal of Medical Virology. 80: 1350-3. PMID 18551608 DOI: 10.1002/jmv.21109 | 0.038 | |||
| 2011 | Williams ME, Connors JM, Dreyling MH, Gascoyne RD, Kahl BS, Leonard JP, Press OW, Wilson WH. Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. Leukemia & Lymphoma. 52: 24-33. PMID 21133727 DOI: 10.3109/10428194.2010.532893 | 0.037 | |||
| 2021 | Kotlov N, Bagaev A, Revuelta MV, Phillip JM, Cacciapuoti MT, Antysheva Z, Svekolkin V, Tikhonova E, Miheecheva N, Kuzkina N, Nos G, Tabbo F, Frenkel F, Ghione P, Tsiper M, ... ... Leonard JP, et al. Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures. Cancer Discovery. PMID 33541860 DOI: 10.1158/2159-8290.CD-20-0839 | 0.037 | |||
| 2008 | Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. The New England Journal of Medicine. 359: 613-26. PMID 18687642 DOI: 10.1056/NEJMra0708875 | 0.037 | |||
| 2014 | Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, Mathew S, Vijay P, Eng K, Ali S, Johnson A, Chang B, Ely S, Elemento O, Mason CE, ... Leonard JP, et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discovery. 4: 1022-35. PMID 25082755 DOI: 10.1158/2159-8290.CD-14-0098 | 0.037 | |||
| 2018 | Rimsza LM, Li H, Braziel RM, Spier CM, Persky DO, Dunlap J, LeBlanc M, Bartlett N, Leonard JP, Smith SM, Press OW, Friedberg JW. Impact of histologic grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica. PMID 29472351 DOI: 10.3324/Haematol.2017.175059 | 0.037 | |||
| 2014 | Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, Nichols C, Emmanouilides CE, Timmerman JM, Gregory SA, Link BK, et al. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1797-803. PMID 24799467 DOI: 10.1200/Jco.2012.43.9273 | 0.037 | |||
| 2010 | Chatterjea D, Hamid E, Leonard JP, Alford S. Phosphorylation-state-dependent regulation of NMDA receptor short-term plasticity modifies hippocampal dendritic Ca2+ transients. Journal of Neurophysiology. 104: 2203-13. PMID 20719921 DOI: 10.1152/jn.01081.2009 | 0.037 | |||
| 2004 | Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, Wahl RL, Kroll S, Coleman M, Goris M, Levy R, Knox SJ. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 7792-8. PMID 15585610 DOI: 10.1158/1078-0432.CCR-04-0756 | 0.037 | |||
| 2018 | Tallarico M, Foster JC, Seisler D, Lafky JM, Hurria A, Jatoi A, Cohen HJ, Muss HB, Bartlett N, Cheson BD, Jung SH, Leonard JP, Byrd JC, Nabhan C. Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). Journal of Geriatric Oncology. PMID 29673807 DOI: 10.1016/j.jgo.2018.03.018 | 0.037 | |||
| 2007 | Mones JV, Coleman M, Kostakoglu L, Furman RR, Chadburn A, Shore TB, Muss D, Stewart P, Kroll S, Vallabhajosula S, Goldsmith SJ, Leonard JP. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement. Leukemia & Lymphoma. 48: 342-8. PMID 17325895 DOI: 10.1080/10428190601059720 | 0.037 | |||
| 2006 | Leonard JP. New antibodies in the treatment of lymphoma. Clinical Advances in Hematology & Oncology : H&O. 4: 196-8. PMID 16736567 | 0.036 | |||
| 2022 | Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M. Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial. Nature Medicine. PMID 36195687 DOI: 10.1038/s41591-022-02070-0 | 0.036 | |||
| 2021 | Campion TR, Sholle ET, Pathak J, Johnson SB, Leonard JP, Cole CL. An architecture for research computing in health to support clinical and translational investigators with electronic patient data. Journal of the American Medical Informatics Association : Jamia. PMID 34850911 DOI: 10.1093/jamia/ocab266 | 0.036 | |||
| 2021 | Shafique M, Fisher TL, Evans EE, Leonard JE, Pastore DRE, Mallow CL, Smith ES, Mishra V, Schröder A, Chin K, Beck JT, Baumgart MA, Govindan R, Gabrail NY, Spira AI, et al. A Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33820783 DOI: 10.1158/1078-0432.CCR-20-4792 | 0.036 | |||
| 2021 | Trevino KM, Martin P, Chen Z, Leonard JP. Worsening Quality of Life in Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients in Active Surveillance: A 12-Month Longitudinal Study. Clinical Lymphoma, Myeloma & Leukemia. PMID 34479847 DOI: 10.1016/j.clml.2021.08.001 | 0.036 | |||
| 2019 | Birket MJ, Raibaud S, Lettieri M, Adamson AD, Letang V, Cervello P, Redon N, Ret G, Viale S, Wang B, Biton B, Guillemot JC, Mikol V, Leonard JP, Hanley NA, et al. A Human Stem Cell Model of Fabry Disease Implicates LIMP-2 Accumulation in Cardiomyocyte Pathology. Stem Cell Reports. PMID 31378672 DOI: 10.1016/j.stemcr.2019.07.004 | 0.036 | |||
| 2016 | Pera B, Tang T, Marullo R, Yang SN, Ahn H, Patel J, Elstrom R, Ruan J, Furman R, Leonard J, Cerchietti L, Martin P. Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients. Clinical Epigenetics. 8: 79. PMID 27453763 DOI: 10.1186/s13148-016-0245-y | 0.036 | |||
| 2017 | Leonard JP, Martin P, Roboz GJ. Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017726745. PMID 28654364 DOI: 10.1200/JCO.2017.72.6745 | 0.035 | |||
| 2014 | Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, Spurgeon SE, Andritsos LA, Gopal AK, Leonard JP, Eisenfeld AJ, Bannink JE, Stromatt SC, Furman RR. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 123: 1302-8. PMID 24381226 DOI: 10.1182/blood-2013-07-512137 | 0.035 | |||
| 2010 | Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas New England Journal of Medicine. 363: 1812-1821. PMID 21047225 DOI: 10.1056/NEJMoa1002965 | 0.035 | |||
| 2010 | Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, et al. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. American Journal of Hematology. 85: 664-9. PMID 20645430 DOI: 10.1002/Ajh.21777 | 0.035 | |||
| 2007 | Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, Hainsworth J, Sparano JA, Tsai DE, Horning S, Krieg AM, Weiner GJ. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6168-74. PMID 17947483 DOI: 10.1158/1078-0432.CCR-07-0815 | 0.035 | |||
| 2015 | Goldstein RL, Yang SN, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, Shaknovich R, Tam W, Leonard JP, Chiosis G, Cerchietti L, Melnick A. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. The Journal of Clinical Investigation. 2015. PMID 26529251 DOI: 10.1172/Jci80714 | 0.035 | |||
| 2006 | Dosik AD, Coleman M, Kostakoglu L, Furman RR, Fiore JM, Muss D, Niesvizky R, Shore T, Schuster MW, Stewart P, Vallabhajosula S, Goldsmith SJ, Leonard JP. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer. 106: 616-22. PMID 16362977 DOI: 10.1002/cncr.21606 | 0.035 | |||
| 2021 | Toure A, Luan D, Wu Y, Christos PJ, Leonard JP, Martin P. An Assessment of Race as a Risk Factor for Doxorubicin-Related Cardiotoxicity in Diffuse Large B-Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. PMID 34446381 DOI: 10.1016/j.clml.2021.07.035 | 0.035 | |||
| 2003 | Siegel AB, Leonard JP. Hodgkin's lymphoma in HIV: unusual presentations and improving outcomes. Clinical Advances in Hematology & Oncology : H&O. 1: 616-7. PMID 16258459 | 0.034 | |||
| 2002 | Dunussi-Joannopoulos K, Zuberek K, Runyon K, Hawley RG, Wong A, Erickson J, Herrmann S, Leonard JP. Efficacious immunomodulatory activity of the chemokine stromal cell-derived factor 1 (SDF-1): local secretion of SDF-1 at the tumor site serves as T-cell chemoattractant and mediates T-cell-dependent antitumor responses. Blood. 100: 1551-8. PMID 12176869 | 0.034 | |||
| 2022 | Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M. Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial. Nature Medicine. PMID 35941373 DOI: 10.1038/s41591-022-01919-8 | 0.034 | |||
| 2015 | Patnaik A, Weiss GJ, Leonard JE, Rasco D, Sachdev JC, Fisher TL, Winter LA, Reilly C, Parker RB, Mutz D, Blaydorn L, Tolcher AW, Zauderer M, Ramanathan RK. Safety, Pharmacokinetics and Pharmacodynamics of a Humanized anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26446947 DOI: 10.1158/1078-0432.Ccr-15-0431 | 0.034 | |||
| 2020 | Shah MA, Emlen MF, Shore T, Mayer S, Leonard JP, Rossi A, Martin P, Ritchie E, Niesvizky R, Pastore R, Cigler T, De Sancho M, Scheff R, Van Besien K, Roboz G, et al. Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. Ca: a Cancer Journal For Clinicians. PMID 32662880 DOI: 10.3322/caac.21627 | 0.034 | |||
| 2007 | Siegel AB, Lachs M, Coleman M, Leonard JP. Lymphoma in elderly patients: novel functional assessment techniques provide better discrimination among patients than traditional performance status measures. Clinical Lymphoma & Myeloma. 7: 65-9. PMID 16879772 DOI: 10.3816/CLM.2006.n.041 | 0.033 | |||
| 2021 | Calvo-Vidal MN, Zamponi N, Krumsiek J, Stockslager MA, Revuelta MV, Phillip JM, Marullo R, Tikhonova E, Kotlov N, Patel J, Yang SN, Yang L, Taldone T, Thieblemont C, Leonard JP, et al. Oncogenic HSP90 facilitates metabolic alterations in aggressive B-cell lymphomas. Cancer Research. PMID 34479963 DOI: 10.1158/0008-5472.CAN-21-2734 | 0.033 | |||
| 2007 | Leonard JP, Friedberg JW, Hagemeister FB, Levine AM. Combination treatment approaches and novel therapies for lymphoma. Clinical Advances in Hematology & Oncology : H&O. 5: 4-20; quiz 1 p follo. PMID 18154235 | 0.033 | |||
| 2021 | Mehta-Shah N, Lunning MA, Moskowitz AJ, Boruchov AM, Ruan J, Lynch P, Hamlin PA, Leonard J, Matasar MJ, Myskowski PL, Marzouk E, Nair S, Sholklapper T, Minnal V, Palomba ML, et al. Romidepsin and lenalidomide based regimens have efficacy in relapsed/refractory lymphoma: combined analysis of two phase I studies with expansion cohorts. American Journal of Hematology. PMID 34251048 DOI: 10.1002/ajh.26288 | 0.033 | |||
| 2024 | Yamshon S, Gribbin C, Alhomoud M, Chokr N, Chen Z, Demetres M, Pasciolla M, Leonard J, Shore T, Martin P. Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis. Clinical Lymphoma, Myeloma & Leukemia. PMID 38582666 DOI: 10.1016/j.clml.2024.02.007 | 0.033 | |||
| 2020 | Ha CS, LeBlanc M, Schöder H, Pinnix CC, Bartlett NL, Evens AM, Hsi ED, Rimsza L, Knopp MV, Zhang J, Leonard JP, Kahl BS, Li H, Smith S, Constine LS, et al. Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. Leukemia & Lymphoma. 1-6. PMID 32452714 DOI: 10.1080/10428194.2020.1768388 | 0.032 | |||
| 2019 | Al-Mansour Z, Li H, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Smith SM, Marcellus DC, Barton KP, Mills GM, LeBlanc M, ... ... Leonard JP, et al. Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. Leukemia & Lymphoma. 1-8. PMID 30628511 DOI: 10.1080/10428194.2018.1563691 | 0.032 | |||
| 2014 | Smith ES, Jonason A, Reilly C, Veeraraghavan J, Fisher T, Doherty M, Klimatcheva E, Mallow C, Cornelius C, Leonard JE, Marchi N, Janigro D, Argaw AT, Pham T, Seils J, et al. SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease. Neurobiology of Disease. 73: 254-268. PMID 25461192 DOI: 10.1016/J.Nbd.2014.10.008 | 0.032 | |||
| 2011 | Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM, Lacasce A, Morrison J, Elstrom R, Ely S, Chadburn A, Cesarman E, Coleman M, Leonard JP. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 690-7. PMID 21189393 DOI: 10.1200/Jco.2010.31.1142 | 0.032 | |||
| 2020 | Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, et al. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2000999. PMID 32658627 DOI: 10.1200/Jco.20.00999 | 0.032 | |||
| 2010 | Elstrom RL, Leonard JP. FDG-PET scans in patients with lymphoma. Current Hematologic Malignancy Reports. 3: 197-203. PMID 20425466 DOI: 10.1007/s11899-008-0028-4 | 0.032 | |||
| 2017 | Casulo C, O'Connor O, Shustov A, Fanale M, Friedberg JW, Leonard JP, Kahl BS, Little RF, Pinter-Brown L, Advani R, Horwitz S. T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. Journal of the National Cancer Institute. 109. PMID 28040682 DOI: 10.1093/jnci/djw248 | 0.032 | |||
| 2004 | Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. British Journal of Haematology. 125: 232-9. PMID 15059147 DOI: 10.1111/j.1365-2141.2004.04889.x | 0.032 | |||
| 2015 | Leonard JP, Jung SH, Johnson J, Pitcher BN, Bartlett NL, Blum KA, Czuczman M, Giguere JK, Cheson BD. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26304886 DOI: 10.1200/Jco.2014.59.9258 | 0.031 | |||
| 2023 | Russler-Germain DA, Krysiak K, Ramirez C, Mosior M, Watkins MP, Gomez F, Skidmore ZL, Trani L, Gao F, Geyer S, Cashen AF, Mehta-Shah N, Kahl BS, Bartlett NL, Alderuccio JP, ... ... Leonard JP, et al. Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes at Diagnosis (Alliance A151303). Blood Advances. PMID 37493986 DOI: 10.1182/bloodadvances.2023010779 | 0.031 | |||
| 2008 | Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K, Larow A, Lent R, Mark T, Cho HJ, Shore T, ... ... Leonard JP, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 111: 1101-9. PMID 17989313 DOI: 10.1182/Blood-2007-05-090258 | 0.031 | |||
| 2017 | Leonard JM. Central Nervous System Tuberculosis. Microbiology Spectrum. 5. PMID 28281443 DOI: 10.1128/microbiolspec.TNMI7-0044-2017 | 0.031 | |||
| 2015 | Leonard JE, Fisher TL, Winter LA, Cornelius CA, Reilly C, Smith ES, Zauderer M. Nonclinical Safety Evaluation of VX15/2503, a Humanized IgG4 Anti-SEMA4D Antibody. Molecular Cancer Therapeutics. 14: 964-72. PMID 25657333 DOI: 10.1158/1535-7163.Mct-14-0924 | 0.031 | |||
| 2006 | Shore T, Harpel J, Schuster MW, Roboz GJ, Leonard JP, Coleman M, Feldman EJ, Silver RT. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 12: 868-75. PMID 16864057 DOI: 10.1016/j.bbmt.2006.05.006 | 0.031 | |||
| 2022 | Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S, Dogan A, Feldman A, Fend F, Friedberg JW, Gaulard P, ... ... Leonard JP, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. Blood. PMID 35653592 DOI: 10.1182/blood.2022015851 | 0.031 | |||
| 2017 | Rutherford SC, Li V, Ghione P, Chen Z, Martin P, Leonard JP. Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials. British Journal of Haematology. PMID 28677889 DOI: 10.1111/bjh.14839 | 0.031 | |||
| 2016 | Leonard JP, Gregory SA, Smith H, Horner TJ, Williams VC, Giampietro P, Lin TS. CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. PMID 26832194 DOI: 10.1016/j.clml.2015.12.011 | 0.03 | |||
| 2014 | Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 123: 3406-13. PMID 24615776 DOI: 10.1182/blood-2013-11-538546 | 0.03 | |||
| 2012 | Elstrom RL, Andemariam B, Martin P, Ruan J, Shore TB, Coleman M, Leonard JP, Furman RR. Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma. 53: 1469-73. PMID 22263572 DOI: 10.3109/10428194.2012.656629 | 0.03 | |||
| 2003 | Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T, Talvenheimo J, Montestruque S, Sun J, Elliott G, Thomas J, Ferbas J, Kern B, Briddell R, ... Leonard JP, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 3982S-90S. PMID 14506197 | 0.03 | |||
| 2008 | Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, George P, Leonard J, Kaufmann T. Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leukemia & Lymphoma. 49: 447-50. PMID 18297520 DOI: 10.1080/10428190701837330 | 0.029 | |||
| 2009 | Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, Elstrom R, Niesvizky R, Ely S, Diliberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. Outcome of deferred initial therapy in mantle-cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1209-13. PMID 19188674 DOI: 10.1200/Jco.2008.19.6121 | 0.029 | |||
| 2017 | Straub J, Freifeld O, Rosman G, Leonard JJ, Fisher JW. The Manhattan Frame Model - Manhattan World Inference in the Space of Surface Normals. Ieee Transactions On Pattern Analysis and Machine Intelligence. PMID 28166490 DOI: 10.1109/Tpami.2017.2662686 | 0.029 | |||
| 2018 | Nastoupil LJ, Flowers CR, Leonard JP. Sequencing of therapies in relapsed follicular lymphoma. Hematology. American Society of Hematology. Education Program. 2018: 189-193. PMID 30504309 DOI: 10.1182/asheducation-2018.1.189 | 0.029 | |||
| 2020 | Flowers C, Leonard JP, Fowler N. Lenalidomide in follicular lymphoma. Blood. PMID 32236519 DOI: 10.1182/blood.2019001751 | 0.029 | |||
| 2018 | Qu X, Li H, Braziel RM, Passerini V, Rimsza LM, Hsi ED, Leonard JP, Smith SM, Kridel R, Press O, Weigert O, LeBlanc M, Friedberg JW, Fang M. Genomic alterations important for the prognosis in patients with follicular lymphoma treated on SWOG study S0016. Blood. PMID 30446494 DOI: 10.1182/blood-2018-07-865428 | 0.028 | |||
| 2002 | Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 43: 1018-27. PMID 12163626 | 0.028 | |||
| 2021 | Klawon DEJ, Gilmore DC, Leonard JD, Miller CH, Chao JL, Walker MT, Duncombe RK, Tung KS, Adams EJ, Savage PA. Altered selection on a single self-ligand promotes susceptibility to organ-specific T cell infiltration. The Journal of Experimental Medicine. 218. PMID 33914024 DOI: 10.1084/jem.20200701 | 0.028 | |||
| 2010 | Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 115: 2578-85. PMID 19965662 DOI: 10.1182/Blood-2009-08-236471 | 0.028 | |||
| 2022 | Harkins RA, Patel S, Lee MJ, Switchenko JM, Ansell SM, Bartlett NL, Blum K, Cashen AF, Casulo C, Friedberg JW, Johnston P, Kahl BS, Leonard JP, Link BK, Lossos IS, et al. Improving eligibility criteria for first-line trials for patients with DLBCL using a U.S.-based Delphi-method survey. Blood Advances. PMID 35100356 DOI: 10.1182/bloodadvances.2021006504 | 0.028 | |||
| 2008 | Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, LaRow A, Pearse RN, Harpel J, Shore T, Schuster MW, Leonard JP, Christos PJ, Coleman M, Niesvizky R. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 14: 795-8. PMID 18541199 DOI: 10.1016/j.bbmt.2008.04.008 | 0.028 | |||
| 2020 | Leonard JP. Mantle Cell Lymphoma: Biologic Insights to Bedside Impact. Hematology/Oncology Clinics of North America. 34: xiii-xiv. PMID 32861292 DOI: 10.1016/j.hoc.2020.07.001 | 0.027 | |||
| 2022 | Leonard J, Matsushita A, Kawasaki M. Morphology and receptive field organization of a temporal processing region in Apteronotus albifrons. Journal of Comparative Physiology. a, Neuroethology, Sensory, Neural, and Behavioral Physiology. PMID 35233699 DOI: 10.1007/s00359-022-01546-1 | 0.027 | |||
| 2002 | Ahmed Z, Doward AI, Pryce G, Taylor DL, Pocock JM, Leonard JP, Baker D, Cuzner ML. A role for caspase-1 and -3 in the pathology of experimental allergic encephalomyelitis : inflammation versus degeneration. The American Journal of Pathology. 161: 1577-86. PMID 12414506 DOI: 10.1016/S0002-9440(10)64436-7 | 0.027 | |||
| 2016 | Shen C, Ng TK, Leonard JT, Pourhashemi A, Nakamura S, DenBaars SP, Speck JS, Alyamani AY, El-Desouki MM, Ooi BS. High-brightness semipolar (2021¯) blue InGaN/GaN superluminescent diodes for droop-free solid-state lighting and visible-light communications. Optics Letters. 41: 2608-2611. PMID 27244426 DOI: 10.1364/Ol.41.002608 | 0.027 | |||
| 2011 | Wilson SR, Leonard JP, Geyer JT, Osborne JR, Weinsaft JW. A worrisome interventricular septum: more than meets the eye. Journal of the American College of Cardiology. 58: e43. PMID 22133864 DOI: 10.1016/J.Jacc.2011.06.069 | 0.026 | |||
| 2023 | Rosenberg SM, McCue S, He J, Lafky JM, Carey LA, Galanis E, Leonard JP, Meyerhardt J, Ng K, Schwartz GK, Stock W, Paskett ED, Partridge AH, George S. Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017. Cancer. PMID 37916800 DOI: 10.1002/cncr.35078 | 0.026 | |||
| 2010 | Link BK, Martin P, Kaminski MS, Goldsmith SJ, Coleman M, Leonard JP. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3035-41. PMID 20458031 DOI: 10.1200/JCO.2009.27.8325 | 0.026 | |||
| 2005 | Czuczman MS, Thall A, Witzig TE, Vose JM, Younes A, Emmanouilides C, Miller TP, Moore JO, Leonard JP, Gordon LI, Sweetenham J, Alkuzweny B, Finucane DM, Leigh BR. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4390-8. PMID 15994148 DOI: 10.1200/Jco.2005.09.018 | 0.026 | |||
| 2010 | Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L, Melnick A, Coleman M, Leonard JP. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clinical Lymphoma, Myeloma & Leukemia. 10: 192-6. PMID 20511164 DOI: 10.3816/Clml.2010.N.030 | 0.026 | |||
| 2017 | LaGanke C, Samkoff L, Edwards K, Jung Henson L, Repovic P, Lynch S, Stone L, Mattson D, Galluzzi A, Fisher TL, Reilly C, Winter LA, Leonard JE, Zauderer M. Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial. Neurology(R) Neuroimmunology & Neuroinflammation. 4: e367. PMID 28642891 DOI: 10.1212/Nxi.0000000000000367 | 0.026 | |||
| 2012 | Elstrom RL, Martin P, Hurtado Rua S, Shore TB, Furman RR, Ruan J, Pearse RN, Coleman M, Mark T, Leonard JP, Gergis U. Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. American Journal of Hematology. 87: 433-5. PMID 22367772 DOI: 10.1002/ajh.23108 | 0.026 | |||
| 2005 | Marusic S, Leach MW, Pelker JW, Azoitei ML, Uozumi N, Cui J, Shen MW, DeClercq CM, Miyashiro JS, Carito BA, Thakker P, Simmons DL, Leonard JP, Shimizu T, Clark JD. Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis. The Journal of Experimental Medicine. 202: 841-51. PMID 16172261 DOI: 10.1084/jem.20050665 | 0.025 | |||
| 2006 | Goldenberg DM, Stein R, Leonard JP, Steinfeld SD, Dörner T, Burmester GR. B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: comment on the editorial by St. Clair and Tedder. Arthritis and Rheumatism. 54: 2344; author reply 2. PMID 16802381 DOI: 10.1002/art.21937 | 0.025 | |||
| 2010 | Williams ME, Dreyling MH, Kahl BS, Leonard JP, O'Connor OA, Press OW, Wilson WH. Mantle cell lymphoma: report of the 2009 Mantle Cell Lymphoma Consortium Workshop. Leukemia & Lymphoma. 51: 390-8. PMID 20038219 DOI: 10.3109/10428190903503453 | 0.025 | |||
| 2008 | Rutherford SC, Andemariam B, Philips SM, Elstrom RL, Chadburn A, Furman RR, Niesvizky R, Martin P, Fahey TJ, Coleman M, Goldsmith SJ, Leonard JP. FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma. Leukemia & Lymphoma. 49: 719-26. PMID 18398739 DOI: 10.1080/10428190801927387 | 0.025 | |||
| 2012 | Natoli TA, Husson H, Rogers KA, Smith LA, Wang B, Budman Y, Bukanov NO, Ledbetter SR, Klinger KW, Leonard JP, Ibraghimov-Beskrovnaya O. Loss of GM3 synthase gene, but not sphingosine kinase 1, is protective against murine nephronophthisis-related polycystic kidney disease. Human Molecular Genetics. 21: 3397-407. PMID 22563011 DOI: 10.1093/hmg/dds172 | 0.025 | |||
| 2006 | Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4867-74. PMID 17001068 DOI: 10.1200/JCO.2006.07.9665 | 0.025 | |||
| 2016 | Ruan J, Leonard JP. Lenalidomide plus Rituximab for Mantle-Cell Lymphoma. The New England Journal of Medicine. 374: 793. PMID 26933862 DOI: 10.1056/NEJMc1515465 | 0.024 | |||
| 2019 | Blum KA, Polley MY, Jung SH, Dockter TJ, Anderson S, Hsi ED, Wagner-Johnston N, Christian B, Atkins J, Cheson BD, Leonard JP, Bartlett NL. Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). Cancer. PMID 31174236 DOI: 10.1002/cncr.32289 | 0.024 | |||
| 2020 | Thanarajasingam G, Leonard JP, Witzig TE, Habermann TM, Blum KA, Bartlett NL, Flowers CR, Pitcher BN, Jung SH, Atherton PJ, Tan A, Novotny PJ, Dueck AC. Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. The Lancet. Haematology. 7: e490-e497. PMID 32470440 DOI: 10.1016/S2352-3026(20)30067-3 | 0.024 | |||
| 2019 | Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, Ridling L, Dittus C, Chen Z, Huang X, Inghirami G, DiLiberto M, Chen-Kiang S, Leonard JP. A phase I trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. PMID 30692121 DOI: 10.1182/blood-2018-11-886457 | 0.024 | |||
| 2016 | Balu D, Larson JR, Schmidt JV, Wirtshafter D, Yevtodiyenko A, Leonard JP. Behavioral and Physiological Characterization of PKC-dependent Phosphorylation in the Grin2a∆PKC mouse. Brain Research. PMID 27317637 DOI: 10.1016/J.Brainres.2016.06.022 | 0.024 | |||
| 2023 | Mulvey E, Leonard JP. Follicular lymphoma grade 3B: low grade, high grade or should we skip the grade? Haematologica. PMID 37199128 DOI: 10.3324/haematol.2023.282893 | 0.024 | |||
| 2002 | Eppihimer MJ, Gunn J, Freeman GJ, Greenfield EA, Chernova T, Erickson J, Leonard JP. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation (New York, N.Y. : 1994). 9: 133-45. PMID 11932780 DOI: 10.1038/sj/mn/7800123 | 0.024 | |||
| 2019 | Martin P, Ruan J, Furman R, Rutherford S, Allan J, Chen Z, Huang X, DiLiberto M, Chen-Kiang S, Leonard JP. A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Leukemia & Lymphoma. 1-5. PMID 31120355 DOI: 10.1080/10428194.2019.1612062 | 0.024 | |||
| 2013 | Evens AM, Advani R, Press OW, Lossos IS, Vose JM, Hernandez-Ilizaliturri FJ, Robinson BK, Otis S, Nadav Dagan L, Abdallah R, Kroll-Desrosiers A, Yarber JL, Sandoval J, Foyil K, Parker LM, ... ... Leonard JP, et al. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 4132-9. PMID 24043736 DOI: 10.1200/Jco.2013.49.8220 | 0.023 | |||
| 2010 | Yang ZJ, McComas K, Gay G, Leonard JP, Dannenberg AJ, Dillon H. Motivation for health information seeking and processing about clinical trial enrollment. Health Communication. 25: 423-36. PMID 20677046 DOI: 10.1080/10410236.2010.483338 | 0.023 | |||
| 2016 | Rimsza L, Fedoriw Y, Staudt LM, Melnick A, Gascoyne R, Crump M, Baizer L, Fu K, Hsi E, Chan JW, McShane L, Leonard JP, Kahl BS, Little RF, Friedberg JW, et al. General Biomarker Recommendations for Lymphoma. Journal of the National Cancer Institute. 108. PMID 27986882 DOI: 10.1093/Jnci/Djw250 | 0.023 | |||
| 2015 | Leonard JD, Narlikar GJ. A nucleotide-driven switch regulates flanking DNA length sensing by a dimeric chromatin remodeler. Molecular Cell. 57: 850-9. PMID 25684208 DOI: 10.1016/J.Molcel.2015.01.008 | 0.023 | |||
| 2009 | Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, Bosly A, Pinter-Brown L, Kennedy D, Sievers EL, Gopal AK. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. British Journal of Haematology. 146: 171-9. PMID 19466965 DOI: 10.1111/j.1365-2141.2009.07740.x | 0.023 | |||
| 2018 | Jayasinghe N, Isabel Moallem B, Kakoullis M, Ojie MJ, Sar-Graycar L, Wyka K, Reid MC, Leonard JP. Establishing the Feasibility of a Tablet-Based Consent Process with Older Adults: A Mixed-Methods Study. The Gerontologist. PMID 29757375 DOI: 10.1093/Geront/Gny045 | 0.023 | |||
| 2019 | Hsi ED, Li H, Nixon AB, Schöder H, Bartlett NL, LeBlanc M, Smith S, Kahl BS, Leonard JP, Evens AM, Scott DW, Rimsza LM, Friedberg JW. Serum levels of TARC, MDC, IL10 and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. Blood. PMID 30723079 DOI: 10.1182/blood-2018-08-870915 | 0.023 | |||
| 2007 | Kostakoglu L, Leonard JP, Coleman M, Goldsmith SJ. The role of FDG-PET imaging in the management of lymphoma. Clinical Advances in Hematology & Oncology : H&O. 2: 115-21. PMID 16163171 | 0.022 | |||
| 2019 | Gopalsamy SN, Rosenthal KM, Ayers AA, Goy A, Leonard JP, Vose JM, Obholz KL, Armitage JO, Flowers CR. Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma. Leukemia & Lymphoma. 1-9. PMID 30848966 DOI: 10.1080/10428194.2019.1574006 | 0.022 | |||
| 2009 | Leonard JP. Antibody treatment in lymphoma Clinical Advances in Hematology and Oncology. 7: 106-107. PMID 19367250 | 0.022 | |||
| 2007 | Leonard JP. Antibodies in the treatment of lymphoma. Clinical Advances in Hematology & Oncology : H&O. 2: 210-1. PMID 16163182 | 0.022 | |||
| 2010 | Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, Cui Y, Busman T, Elmore SW, Rosenberg SH, Krivoshik AP, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. The Lancet. Oncology. 11: 1149-59. PMID 21094089 DOI: 10.1016/S1470-2045(10)70261-8 | 0.022 | |||
| 2016 | Yonkee BP, Young EC, Lee C, Leonard JT, DenBaars SP, Speck JS, Nakamura S. Demonstration of a III-nitride edge-emitting laser diode utilizing a GaN tunnel junction contact. Optics Express. 24: 7816-7822. PMID 27137064 DOI: 10.1364/Oe.24.007816 | 0.022 | |||
| 2003 | Coleman M, Leonard J, Lyons L, Szelenyi H, Niesvizky R. Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Seminars in Oncology. 30: 270-4. PMID 12720151 DOI: 10.1053/sonc.2003.50044 | 0.022 | |||
| 2008 | Martin P, Coleman M, Leonard JP. Progress in mantle-cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 481-3. PMID 19075257 DOI: 10.1200/JCO.2008.19.5032 | 0.022 | |||
| 2021 | Orfali N, Jhanwar Y, Koo C, Pasciolla M, Baldo M, Cuvilly E, Furman R, Gergis U, Greenberg J, Guarneri D, Hsu JM, Leonard JP, Mark T, Mayer S, Maignan K, et al. Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma. Leukemia & Lymphoma. 1-15. PMID 33586581 DOI: 10.1080/10428194.2021.1881516 | 0.021 | |||
| 2012 | Yang ZJ, McComas KA, Gay GK, Leonard JP, Dannenberg AJ, Dillon H. Comparing decision making between cancer patients and the general population: thoughts, emotions, or social influence? Journal of Health Communication. 17: 477-94. PMID 22376222 DOI: 10.1080/10810730.2011.635774 | 0.021 | |||
| 2015 | Elstrom RL, Ruan J, Christos PJ, Martin P, Lebovic D, Osborne J, Goldsmith S, Greenberg J, Furman RR, Avram A, Putman R, Chapman E, Mazumdar M, Griffith K, Coleman M, ... Leonard JP, et al. Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab. Leukemia & Lymphoma. 56: 342-6. PMID 24730538 DOI: 10.3109/10428194.2014.914195 | 0.021 | |||
| 2018 | Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schöder H, Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, et al. CALBG 50604: risk-adapted treatment of non-bulky early stage Hodgkin lymphoma based on interim PET. Blood. PMID 30049811 DOI: 10.1182/blood-2018-01-827246 | 0.021 | |||
| 2007 | Martin P, Leonard JP. IL-4 as therapy for non-Hodgkin's lymphoma: possibilities but major challenges. Leukemia & Lymphoma. 48: 1259-60. PMID 17613750 DOI: 10.1080/10428190701416481 | 0.02 | |||
| 2005 | Cui J, Pazdziorko S, Miyashiro JS, Thakker P, Pelker JW, Declercq C, Jiao A, Gunn J, Mason L, Leonard JP, Williams CM, Marusic S. TH1-mediated airway hyperresponsiveness independent of neutrophilic inflammation. The Journal of Allergy and Clinical Immunology. 115: 309-15. PMID 15696086 DOI: 10.1016/j.jaci.2004.10.046 | 0.02 | |||
| 2010 | Ruan J, Martin P, Coleman M, Furman RR, Cheung K, Faye A, Elstrom R, Lachs M, Hajjar KA, Leonard JP. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer. 116: 2655-64. PMID 20235190 DOI: 10.1002/Cncr.25055 | 0.02 | |||
| 2023 | Soliman E, Leonard J, Basso EKG, Gershenson I, Ju J, Mills J, de Jager C, Kaloss AM, Elhassanny M, Pereira D, Chen M, Wang X, Theus MH. Efferocytosis is restricted by axon guidance molecule EphA4 via ERK/Stat6/MERTK signaling following brain injury. Journal of Neuroinflammation. 20: 256. PMID 37941008 DOI: 10.1186/s12974-023-02940-5 | 0.02 | |||
| 2008 | Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, George P, Kaufman TP, Leonard JP. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer. 112: 2228-32. PMID 18338745 DOI: 10.1002/cncr.23422 | 0.02 | |||
| 2024 | Longhurst HJ, Lindsay K, Petersen RS, Fijen LM, Gurugama P, Maag D, Butler JS, Shah MY, Golden A, Xu Y, Boiselle C, Vogel JD, Abdelhady AM, Maitland ML, McKee MD, ... ... Leonard J, et al. CRISPR-Cas9 In Vivo Gene Editing of for Hereditary Angioedema. The New England Journal of Medicine. 390: 432-441. PMID 38294975 DOI: 10.1056/NEJMoa2309149 | 0.019 | |||
| 2016 | Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, ... ... Leonard JP, et al. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27069074 DOI: 10.1200/Jco.2015.63.1119 | 0.019 | |||
| 2008 | Blinder VS, Chadburn A, Furman RR, Mathew S, Leonard JP. Improving outcomes for patients with Burkitt lymphoma and HIV. Aids Patient Care and Stds. 22: 175-87. PMID 18290753 DOI: 10.1089/apc.2007.0124 | 0.019 | |||
| 2010 | Oliansky DM, Gordon LI, King J, Laport G, Leonard JP, McLaughlin P, Soiffer RJ, van Besien KW, Werner M, Jones RB, McCarthy PL, Hahn T. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 16: 443-68. PMID 20114084 DOI: 10.1016/j.bbmt.2010.01.008 | 0.019 | |||
| 2021 | Jurgens EM, Ketas TJ, Zhao Z, Satlin MJ, Small CB, Sukhu A, Francomano E, Klasse PJ, Garcia A, Nguyenduy E, Bhavsar E, Formenti S, Furman R, Moore JP, Leonard JP, et al. Serologic response to mRNA COVID-19 vaccination in lymphoma patients. American Journal of Hematology. PMID 34390501 DOI: 10.1002/ajh.26322 | 0.019 | |||
| 2021 | Luan D, Wu Y, Goldstein J, Rutherford S, Leonard JP, Martin P. Evaluation of the prognostic utility of bone marrow biopsy in diffuse large B-Cell lymphoma in the SEER-Medicare dataset. Leukemia & Lymphoma. 1-14. PMID 33627025 DOI: 10.1080/10428194.2021.1889540 | 0.018 | |||
| 2023 | Sinha Gregory N, Shukla AP, Noel JJ, Alonso LC, Moxley J, Crawford AJ, Martin P, Kumar S, Leonard JP, Czaja SJ. The feasibility, acceptability, and usability of telehealth visits. Frontiers in Medicine. 10: 1198096. PMID 37538312 DOI: 10.3389/fmed.2023.1198096 | 0.018 | |||
| 2019 | Trevino KM, Rutherford SC, Marte C, Ouyang DJ, Martin P, Prigerson HG, Leonard JP. Illness Understanding and Advance Care Planning in Patients with Advanced Lymphoma. Journal of Palliative Medicine. PMID 31633432 DOI: 10.1089/jpm.2019.0311 | 0.018 | |||
| 2019 | Yap TA, Winter JN, Giulino-Roth L, Longley J, Lopez JS, Michot JM, Leonard JP, Ribrag V, McCabe MT, Creasy CL, Stern M, Pene Dumitrescu T, Wang X, Frey S, Carver J, et al. Phase 1 study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematological and solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31471312 DOI: 10.1158/1078-0432.CCR-18-4121 | 0.018 | |||
| 2022 | Leonard JP. POD24 in follicular lymphoma: time to be "wise". Blood. 139: 1609-1610. PMID 35298602 DOI: 10.1182/blood.2021013437 | 0.018 | |||
| 2018 | Makino E, Klodnitsky H, Leonard J, Lillie J, Lund TC, Marshall J, Nietupski J, Orchard PJ, Miller WP, Phaneuf C, Tietz D, Varban ML, Donovan M, Belenki A. Publisher Correction: Fast, sensitive method for trisaccharide biomarker detection in mucopolysaccharidosis type 1. Scientific Reports. 8: 4994. PMID 29556060 DOI: 10.1038/S41598-018-23332-3 | 0.017 | |||
| 2017 | Leonard JD, Gilmore DC, Dileepan T, Nawrocka WI, Chao JL, Schoenbach MH, Jenkins MK, Adams EJ, Savage PA. Identification of Natural Regulatory T Cell Epitopes Reveals Convergence on a Dominant Autoantigen. Immunity. PMID 28709804 DOI: 10.1016/J.Immuni.2017.06.015 | 0.017 | |||
| 2015 | Weinstock DM, Dalla-Favera R, Gascoyne RD, Leonard JP, Levy R, Lossos IS, Melnick AM, Nowakowski GS, Press OW, Savage KJ, Shipp MA, Staudt LM. A roadmap for discovery and translation in lymphoma. Blood. 125: 2175-7. PMID 25814490 DOI: 10.1182/Blood-2015-01-623777 | 0.017 | |||
| 2018 | Makino E, Klodnitsky H, Leonard J, Lillie J, Lund TC, Marshall J, Nietupski J, Orchard PJ, Miller WP, Phaneuf C, Tietz D, Varban ML, Donovan M, Belenki A. Fast, sensitive method for trisaccharide biomarker detection in mucopolysaccharidosis type 1. Scientific Reports. 8: 3681. PMID 29487322 DOI: 10.1038/S41598-018-22078-2 | 0.016 | |||
| 2015 | Weidner AS, Panarelli NC, Geyer JT, Bhavsar EB, Furman RR, Leonard JP, Jessurun J, Yantiss RK. Idelalisib-associated Colitis: Histologic Findings in 14 Patients. The American Journal of Surgical Pathology. 39: 1661-7. PMID 26448188 DOI: 10.1097/PAS.0000000000000522 | 0.016 | |||
| 2022 | Rutherford SC, Yin J, Pederson L, Perez Burbano G, LaPlant B, Shadman M, Li H, LeBlanc ML, Kenkre VP, Hong F, Blum KA, Dockter T, Martin P, Jung SH, Grant B, ... ... Leonard JP, et al. Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2102301. PMID 35787017 DOI: 10.1200/JCO.21.02301 | 0.016 | |||
| 2006 | Ruan J, Leonard JP. Mantle cell lymphoma: current concept in biology and treatment Cancer Treatment and Research. 131: 141-159. PMID 16704169 | 0.016 | |||
| 2024 | Fritsch LE, Kelly C, Leonard J, Jager C, Wei X, Brindley S, Harris EA, Kaloss AM, DeFoor N, Paul S, O'Malley H, Ju J, Olsen ML, Theus MH, Pickrell AM. STING-dependent signaling in microglia or peripheral immune cells orchestrates the early inflammatory response and influences brain injury outcome. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 38360749 DOI: 10.1523/JNEUROSCI.0191-23.2024 | 0.016 | |||
| 2010 | Song Z, Lu P, Furman RR, Leonard JP, Martin P, Tyrell L, Lee FY, Knowles DM, Coleman M, Wang YL. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 587-99. PMID 20068106 DOI: 10.1158/1078-0432.CCR-09-1519 | 0.016 | |||
| 2009 | Mallik A, Leonard JP. Reality of complementary and alternative medicine in lymphoma patients: hope, hype, or help? American Journal of Hematology. 84: 785-7. PMID 19894246 DOI: 10.1002/ajh.21567 | 0.016 | |||
| 2021 | Trevino KM, Martin P, Saracino R, Leonard JP. Unmet need for mental health services in indolent lymphoma: age differences over one-year post-diagnosis. Leukemia & Lymphoma. 62: 1370-1378. PMID 34082646 DOI: 10.1080/10428194.2021.1872071 | 0.016 | |||
| 2023 | Mahmood SS, Riedell PA, Feldman S, George G, Sansoterra SA, Althaus T, Rehman M, Mead E, Liu JE, Devereux RB, Weinsaft JW, Kim J, Balkan L, Barbar T, Lee Chuy K, ... ... Leonard JP, et al. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients. European Heart Journal. PMID 36939851 DOI: 10.1093/eurheartj/ehad117 | 0.015 | |||
| 2022 | Luan D, Martin P, Leonard JP, Trevino KM. Age Differences in Clinical Trial Understanding in Non-Hodgkin Lymphoma Patients. Clinical Lymphoma, Myeloma & Leukemia. PMID 35307317 DOI: 10.1016/j.clml.2022.02.003 | 0.015 | |||
| 2022 | Pinheiro LC, Soroka O, Kern LM, Leonard JP, Safford MM. Racial Disparities in Diabetes-Related Emergency Department Visits and Hospitalizations Among Cancer Survivors. Jco Oncology Practice. OP2100684. PMID 35133858 DOI: 10.1200/OP.21.00684 | 0.015 | |||
| 2010 | Janet Yang Z, McComas K, Gay G, Leonard JP, Dannenberg AJ, Dillon H. From information processing to behavioral intentions: exploring cancer patients' motivations for clinical trial enrollment. Patient Education and Counseling. 79: 231-8. PMID 19748204 DOI: 10.1016/J.Pec.2009.08.010 | 0.015 | |||
| 2010 | Czuczman MS, Leonard JP, Williams ME. Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion. Clinical Advances in Hematology & Oncology : H&O. 8: A1-14; quiz A15. PMID 20552750 | 0.015 | |||
| 2005 | Jones ML, Leonard JP. PKC site mutations reveal differential modulation by insulin of NMDA receptors containing NR2A or NR2B subunits. Journal of Neurochemistry. 92: 1431-8. PMID 15748161 DOI: 10.1111/j.1471-4159.2004.02985.x | 0.015 | |||
| 2018 | Rutherford SC, Leonard JP. Bone marrow biopsies not indicated for response assessment in follicular lymphoma trials regardless of type of imaging study - Response to Adams and Kwee. British Journal of Haematology. PMID 29377067 DOI: 10.1111/bjh.15113 | 0.015 | |||
| 2020 | Leonard JP, Tewes ME, Lombardi JV, Wester DW, Campbell TA. Effects of sun angle, lunar illumination, and diurnal temperature on temporal movement rates of sympatric ocelots and bobcats in South Texas. Plos One. 15: e0231732. PMID 32324759 DOI: 10.1371/journal.pone.0231732 | 0.015 | |||
| 2018 | Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, ... ... Leonard JP, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. The New England Journal of Medicine. 378: 1396-1407. PMID 29641966 DOI: 10.1056/Nejmoa1801445 | 0.014 | |||
| 2020 | Pinheiro LC, Soroka O, Kern LM, Leonard JP, Safford MM. Diabetes care management patterns before and after a cancer diagnosis: A SEER-Medicare matched cohort study. Cancer. PMID 31999848 DOI: 10.1002/cncr.32728 | 0.014 | |||
| 1999 | Adler TR, Leonard JG, Nordgren RK. Improving risk management: moving from risk elimination to risk avoidance Information and Software Technology. 41: 29-34. DOI: 10.1016/S0950-5849(98)00095-0 | 0.014 | |||
| 2012 | Coleman M, Ruan G, Elstrom RL, Martin P, Leonard JP. Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen. Hematology (Amsterdam, Netherlands). 17: S90-2. PMID 22507790 DOI: 10.1179/102453312X13336169155970 | 0.014 | |||
| 2003 | Zuberek K, Ling V, Wu P, Ma HL, Leonard JP, Collins M, Dunussi-Joannopoulos K. Comparable in vivo efficacy of CD28/B7, ICOS/GL50, and ICOS/GL50B costimulatory pathways in murine tumor models: IFNgamma-dependent enhancement of CTL priming, effector functions, and tumor specific memory CTL. Cellular Immunology. 225: 53-63. PMID 14643304 | 0.014 | |||
| 2008 | Brayfield CA, Marra KG, Leonard JP, Tracy Cui X, Gerlach JC. Excimer laser channel creation in polyethersulfone hollow fibers for compartmentalized in vitro neuronal cell culture scaffolds. Acta Biomaterialia. 4: 244-55. PMID 18060849 DOI: 10.1016/J.Actbio.2007.10.004 | 0.014 | |||
| 2004 | Leonard JP. Improved outcomes from dose-dense adjuvant chemotherapy for breast cancer with growth factor support. Current Hematology Reports. 2: 451-2. PMID 14561387 | 0.014 | |||
| 2011 | Martin P, Leonard JP. Advancing through maintenance in mantle cell lymphoma. Leukemia & Lymphoma. 52: 1617-8. PMID 21699376 DOI: 10.3109/10428194.2011.586078 | 0.014 | |||
| 2011 | Gay G, Pollak J, Adams P, Leonard JP. Pilot study of Aurora, a social, mobile-phone-based emotion sharing and recording system. Journal of Diabetes Science and Technology. 5: 325-32. PMID 21527101 DOI: 10.1177/193229681100500219 | 0.014 | |||
| 2023 | Toner K, Allen CE, Jain S, Kahl B, Leonard J, Wasserstrom H, Friedberg JW, Seibel NL, Kelly K. Overcoming barriers to drug development and enrollment in clinical trials for adolescents and young adults with lymphoma. Ejhaem. 4: 921-926. PMID 38024612 DOI: 10.1002/jha2.787 | 0.013 | |||
| 2023 | Campion TR, Sholle ET, Abedian S, Fuld X, McGregor R, Lewis AN, Gripp LT, Leonard JP, Cole CL. Implementation of a commercial federated network of electronic health record data to enable sponsor-initiated clinical trials at an academic medical center. International Journal of Medical Informatics. 182: 105322. PMID 38128198 DOI: 10.1016/j.ijmedinf.2023.105322 | 0.013 | |||
| 2017 | Diefenbach CS, Connors JM, Friedberg JW, Leonard JP, Kahl BS, Little RF, Baizer L, Evens AM, Hoppe RT, Kelly KM, Persky DO, Younes A, Kostakaglu L, Bartlett NL. Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. Journal of the National Cancer Institute. 109. PMID 28040700 DOI: 10.1093/jnci/djw249 | 0.013 | |||
| 2017 | Kawasaki M, Leonard J. Phase-locking behavior in a high-frequency gymnotiform weakly electric fish, Adontosternarchus. Journal of Comparative Physiology. a, Neuroethology, Sensory, Neural, and Behavioral Physiology. PMID 28190119 DOI: 10.1007/S00359-017-1148-X | 0.013 | |||
| 2002 | Marusic S, Miyashiro JS, Douhan J, Konz RF, Xuan D, Pelker JW, Ling V, Leonard JP, Jacobs KA. Local delivery of granulocyte macrophage colony-stimulating factor by retrovirally transduced antigen-specific T cells leads to severe, chronic experimental autoimmune encephalomyelitis in mice. Neuroscience Letters. 332: 185-9. PMID 12399011 DOI: 10.1016/S0304-3940(02)00947-3 | 0.012 | |||
| 2022 | Marte C, George LS, Rutherford SC, Ouyang DJ, Martin P, Leonard JP, Trevino KM. Unmet mental health needs in patients with advanced B-cell lymphomas. Palliative & Supportive Care. 20: 328-333. PMID 35713350 DOI: 10.1017/S1478951521001164 | 0.011 | |||
| 2024 | Rutherford SC, Yin J, Pederson LD, Blum KA, Martin P, Jung SH, Grant B, Rosenbaum CA, Cheson BD, Bartlett NL, Mandrekar SJ, Leonard JP. Impact of Imaging Frequency on Progression Free Survival in Alliance Trials Enrolling Patients with Follicular Lymphoma. Blood Advances. PMID 38266151 DOI: 10.1182/bloodadvances.2023012090 | 0.011 | |||
| 2021 | Pinheiro LC, Soroka O, Kern LM, Higgason N, Leonard JP, Safford MM. Racial disparities in diabetes care among incident breast, prostate, and colorectal cancer survivors: a SEER Medicare study. Journal of Cancer Survivorship : Research and Practice. PMID 33661509 DOI: 10.1007/s11764-021-01003-z | 0.01 | |||
| 2019 | Leonard JP. De-Cell-eration in Therapy for Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900445. PMID 30945958 DOI: 10.1200/JCO.19.00445 | 0.01 | |||
| 2021 | Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, Seitzer J, O'Connell D, Walsh KR, Wood K, Phillips J, Xu Y, Amaral A, Boyd AP, Cehelsky JE, ... ... Leonard J, et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. The New England Journal of Medicine. PMID 34215024 DOI: 10.1056/NEJMoa2107454 | 0.01 | |||
| 2017 | Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L. The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data(). Leukemia & Lymphoma. 1-3. PMID 28573908 DOI: 10.1080/10428194.2017.1323270 | 0.01 | |||
| 2023 | Torka P, Pederson LD, Knopp MV, Poon D, Zhang J, Kahl BS, Higley HR, Kelloff G, Friedberg JW, Schwartz LH, Wilson WH, Leonard JP, Bartlett NL, Schöder H, Ruppert AS. Is local review of positron emission tomography scans sufficient in diffuse large B-cell lymphoma clinical trials? A CALGB 50303 analysis. Cancer Medicine. PMID 36799072 DOI: 10.1002/cam4.5628 | 0.01 | |||
| 2022 | LaCasce AS, Dockter T, Ruppert AS, Kostakoglu L, Schöder H, Hsi E, Bogart J, Cheson B, Wagner-Johnston N, Abramson J, Blum K, Leonard JP, Bartlett NL. Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2200947. PMID 36269899 DOI: 10.1200/JCO.22.00947 | 0.01 | |||
| 2019 | Lee S, Forman CA, Kearns J, Leonard JT, Cohen DA, Nakamura S, DenBaars SP. Demonstration of GaN-based vertical-cavity surface-emitting lasers with buried tunnel junction contacts. Optics Express. 27: 31621-31628. PMID 31684392 DOI: 10.1364/Oe.27.031621 | 0.01 | |||
| 2019 | Bartlett NL, Wilson WH, Leonard JP. Reply to T.M. Weis et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901617. PMID 31532721 DOI: 10.1200/JCO.19.01617 | 0.01 | |||
| 2018 | Rutherford SC, Leonard JP. Management of Relapsed and Refractory Hodgkin Lymphoma in 2018. Jama Oncology. PMID 30003234 DOI: 10.1001/jamaoncol.2018.1767 | 0.01 | |||
| 2017 | Rutherford SC, Leonard JP. Lymphoma "benchmark" or "bench-smudge"? Blood. 130: 1778-1779. PMID 29051150 DOI: 10.1182/blood-2017-08-800730 | 0.01 | |||
| 2017 | Rutherford SC, Leonard JP. The Uncertainties of Rituximab and Related Therapies, 20 Years After Approval. Oncology (Williston Park, N.Y.). 31. PMID 28516440 | 0.01 | |||
| 2015 | Tang T, Chen Z, Praditsuktavorn P, Khoo LP, Ruan J, Lim ST, Tan D, Phipps C, Lee YS, Goh YT, Hwang W, Tao M, Quek R, Farid M, Furman RR, ... Leonard JP, et al. Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. PMID 26796979 DOI: 10.1016/j.clml.2015.12.006 | 0.01 | |||
| 2015 | Pizzi M, Covey S, Mathew S, Liu YC, Ruan J, Leonard JP, Chadburn A. Hepatosplenic T-Cell Lymphoma Mimicking Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia. PMID 26708981 DOI: 10.1016/j.clml.2015.11.019 | 0.01 | |||
| 2015 | Jacobs SE, Lamson DM, Soave R, Guzman BH, Shore TB, Ritchie EK, Zappetti D, Satlin MJ, Leonard JP, van Besien K, Schuetz AN, Jenkins SG, George KS, Walsh TJ. Clinical and molecular epidemiology of human rhinovirus infections in patients with hematologic malignancy. Journal of Clinical Virology : the Official Publication of the Pan American Society For Clinical Virology. 71: 51-8. PMID 26370315 DOI: 10.1016/j.jcv.2015.07.309 | 0.01 | |||
| 2012 | Martin P, Rutherford S, Leonard JP. Splenic lymphomas: is there still a role for splenectomy? Oncology (Williston Park, N.Y.). 26: 204, 206. PMID 22489357 | 0.01 | |||
| 2012 | Jones ML, Liao GY, Malecki R, Li M, Salazar NM, Leonard JP. PI 3-kinase and PKCζ mediate insulin-induced potentiation of NMDA receptor currents in Xenopus oocytes. Brain Research. 1432: 7-14. PMID 22137655 DOI: 10.1016/j.brainres.2011.11.020 | 0.01 | |||
| 2010 | McComas KA, Yang Z, Gay GK, Leonard JP, Dannenberg AJ, Dillon H. Individuals' willingness to talk to their doctors about clinical trial enrollment. Journal of Health Communication. 15: 189-204. PMID 20390986 DOI: 10.1080/10810730903528058 | 0.01 | |||
| 2008 | Bartlett NL, Younes A, Carabasi MH, Forero A, Rosenblatt JD, Leonard JP, Bernstein SH, Bociek RG, Lorenz JM, Hart BW, Barton J. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 111: 1848-54. PMID 18079362 DOI: 10.1182/blood-2007-07-099317 | 0.01 | |||
| 2007 | Niesvizky R, Martínez-Baños D, Jalbrzikowski J, Christos P, Furst J, De Sancho M, Mark T, Pearse R, Mazumdar M, Zafar F, Pekle K, Leonard J, Jayabalan D, Coleman M. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leukemia & Lymphoma. 48: 2330-7. PMID 18067007 DOI: 10.1080/10428190701647887 | 0.01 | |||
| 2007 | Siegel AB, Leonard JP. Therapy for older patients with diffuse large cell lymphoma: targeting the treatment to the patient. Leukemia & Lymphoma. 48: 225-6. PMID 17325880 DOI: 10.1080/10428190601150594 | 0.01 | |||
| 2007 | Thakker P, Leach MW, Kuang W, Benoit SE, Leonard JP, Marusic S. IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. Journal of Immunology (Baltimore, Md. : 1950). 178: 2589-98. PMID 17277169 | 0.01 | |||
| 2006 | Kostakoglu L, Goldsmith SJ, Leonard JP, Christos P, Furman RR, Atasever T, Chandramouly A, Verma S, Kothari P, Coleman M. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer. 107: 2678-87. PMID 17063502 DOI: 10.1002/cncr.22276 | 0.01 | |||
| 2005 | Jelinsky SA, Miyashiro JS, Saraf KA, Tunkey C, Reddy P, Newcombe J, Oestreicher JL, Brown E, Trepicchio WL, Leonard JP, Marusic S. Exploiting genotypic differences to identify genes important for EAE development. Journal of the Neurological Sciences. 239: 81-93. PMID 16214174 DOI: 10.1016/j.jns.2005.08.008 | 0.01 | |||
| 2004 | Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, ... ... Leonard J, et al. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer. 100: 859-68. PMID 14770445 DOI: 10.1002/cncr.11954 | 0.01 | |||
| 2002 | Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer. 94: 879-88. PMID 11920454 | 0.01 | |||
| 1934 | Leonard JG. Brachial Plexus Paralysis Physical Therapy. 14: 3-8. DOI: 10.1093/PTJ/14.1.3 | 0.01 | |||
| Hide low-probability matches. | |||||